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Summary
The intestinal tract of mammals is colonized by a large number of microorganisms 
 including trillions of bacteria that are referred to collectively as the gut microbiota. 
These indigenous microorganisms have co- evolved with the host in a symbiotic rela-
tionship. In addition to metabolic benefits, symbiotic bacteria provide the host with 
several functions that promote immune homeostasis, immune responses, and protec-
tion against pathogen colonization. The ability of symbiotic bacteria to inhibit patho-
gen colonization is mediated via several mechanisms including direct killing, competition 
for limited nutrients, and enhancement of immune responses. Pathogens have evolved 
strategies to promote their replication in the presence of the gut microbiota. 
Perturbation of the gut microbiota structure by environmental and genetic factors in-
creases the risk of pathogen infection, promotes the overgrowth of harmful pathobi-
onts, and the development of inflammatory disease. Understanding the interaction of 
the microbiota with pathogens and the immune system will provide critical insight into 
the pathogenesis of disease and the development of strategies to prevent and treat 
inflammatory disease.
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1  | INTRODUCTION
The oral cavity and the gastrointestinal tract of vertebrates are colo-
nized by large numbers of microorganisms, including bacteria, fungi, ar-
chaea, and protozoa, commonly referred to as the microbiota. Microbes 
colonize mammalian hosts immediately after birth. Many of the resi-
dent bacteria are adapted to the intestinal environment and develop 
complex interactions with other bacteria and host niches to acquire 
nutrients. The composition of the microbiota is largely defined by nu-
trient requirements of individual bacteria and highly variable at differ-
ent locations of the intestinal tract. In neonatal mice, the microbiota is 
less diverse than that of adult individuals, but as the diet changes from 
maternal milk to fiber- rich foods it dramatically changes by the acquisi-
tion of Clostridiales and Bacteroidales, the dominant taxa found in the 
adult intestine.1 The small intestine is rich in mono- and di- saccharides 
as well as amino acids, which support the growth of Proteobacteria 
and Lactobacillales.2 In contrast, the vast majority of available sugars 
in the large intestine are diet and host- derived complex carbohydrates 
which are indigestible by the host. Bacteroidales and Clostridiales har-
bor enzymes that can break down complex polysaccharides, including 
fibers and mucins, and use them as an energy source. Consequently, 
bacteria belonging to the order of Bacteroidales and Clostridiales are 
the dominant populations within the large intestine.
Millions of years of co- evolution between the host and microbes 
have led to a mutualistic symbiosis in which the microbiota contributes 
to many host physiological processes and the host, in turn, provides 
a nutritious and hospitable environment to the microbes. In addition 
to metabolic benefits, the microbiota provides the host with several 
functions that promote the intestinal epithelial barrier, immune ho-
meostasis, optimal immune responses, and protection against patho-
gen colonization. Although the vast majority of intestinal symbionts 
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are mutualistic or commensals (they do not provide a clear benefit to 
the host), some of the indigenous bacteria can promote disease under 
certain circumstances and are commonly referred to as pathobionts. In 
this review, we provide an overview of the current understanding of 
the role of the microbiota in the regulation of immune responses and 
host defense against invading pathogens and pathobionts.
2  | COLONIZATION RESISTANCE
The normal gut symbionts form a stable community that resists the in-
vasion of non- native bacteria and the expansion of pathobionts. This 
phenomenon is known as “colonization resistance,” and has been rec-
ognized since at least the 1950s.3,4 An immature bacterial community 
(such as in infants) or one that is disrupted by antibiotics or diet may 
lose this protective ability. Colonization resistance actually includes 
several related aspects: resistance to initial infection, improved toler-
ance of an established infection, and clearance of the infection. These 
all arise from the constant competition between normal gut residents 
(mutualists, commensals, and pathobionts). The mechanisms bacteria 
use to compete in the gut can be divided into two broad categories: 
direct and indirect (Figure 1).
2.1 | Direct mechanisms of colonization resistance
The microbiota promotes direct colonization resistance through kill-
ing and competition for resources. Bacteria must compete for limited 
nutrient sources in the gut, as well as physical space. At the same time, 
F IGURE  1 Direct and indirect mechanisms of colonization resistance. Direct mechanisms (left): Symbiotic bacteria scavenge nutrients that 
would otherwise be available to pathogens (red, with flagella). Bacteriophages, type 6 secretion systems (T6SS), and bacteriocins may target 
and kill pathogens. Products of bacterial metabolism, such as short- chain fatty acids (SCFAs), can inhibit pathogen growth. Symbiotic bacteria 
produce enzymes that convert conjugated, primary bile acids to secondary bile acids, which can kill some pathogens. Indirect mechanisms (right): 
symbionts produce butyrate which can lower oxygen concentration by stimulating host epithelial cell metabolism. Microbe- associate molecular 
patterns (MAMPs) produced by bacteria and viruses stimulate host innate immunity via TLRs and MyD88, on epithelial cells or dendritic cells 
(DCs). ILC3 and Th17 cells can be activated to produce IL- 22, which promotes secretion of AMPs (antimicrobial peptides) such as Reg3g from 
epithelial cells. B cells produce IgA and IgG antibodies, which can target bacteria in the lumen. Mucus production is stimulated by bacteria, and 
the mucus is decorated with various glycans. These can be cleaved by bacterial enzymes and free sugars, such as fucose, can suppress pathogen 
or pathobiont virulence. The host can also oxidize sugars via reactive nitrogen species produced by inducible nitric oxide synthase (iNOS)
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they have developed an array of armaments to directly kill competi-
tors. Both of these mechanisms tend to act between more closely re-
lated species: similar bacteria tend to utilize similar nutrients or niches, 
and have evolved targeted killing mechanisms to compete with their 
own kind.
2.2 | Killing
Evidence suggests that killing or growth suppression can play a 
dominant role in colonization resistance against some pathogens.5 
Bactericidal molecules are found throughout nature; a large portion of 
these are small polypeptides produced by bacteria, called bacterioc-
ins. These are usually active against closely related bacteria, although 
some have a wider spectrum of activity. Many have been isolated from 
gut bacteria of human and animals, lactic acid bacteria found in fer-
mented foods, and common probiotics like the Bifidobacteria.6 Thus, 
it is reasonable to think that they could be involved in competition in 
the gut. Indeed, strains of Escherichia coli that could make bacterioc-
ins had improved long- term persistence when introduced into mice 
compared to non- producers.7 However, these mice were pretreated 
with streptomycin, which disrupts the normal community structure. 
Like E. coli, bacteriocin- producing Enterococcus faecalis were better 
able to colonize mice, in this case without antibiotic pretreatment. 
The bacteriocin- positive strain could also inhibit colonization by a 
different E. faecalis, an opportunistic pathogen, vancomycin- resistant 
Enterococcus (VRE).8 A human- derived probiotic Lactobacillus strain 
protected mice from Listeria monocytogenes infection, and this was de-
pendent on the Lactobacillus bacteriocin.9 The human probiotic E. coli 
Nissle 1917 may also utilize bacteriocins to compete with and protect 
mice from Salmonella enterica subsp. Typhimurium (S. Typhimurium).10 
There is also evidence that bacteriocins may contribute to continu-
ous intraspecies competition in the gut.11 Still, it is unclear how big 
a role bacteriocins play in colonization resistance to relevant enteric 
pathogens.
Other antibacterial factors are also active in the gut. Bacteriophages 
(viruses that infect bacteria) can have a profound impact on a popu-
lation by lyzing infected cells, and can also affect bacterial fitness by 
transferring genetic information. Advances in sequencing technology 
have revealed abundant and mostly uncharacterized bacteriophages in 
the human gut; these are present as both viral particles and prophages 
(bacteriophage DNA that is integrated into a bacterial genome).12–16 
Prophages may be activated during inflammation,17 and the viral com-
munity may be different in people with inflammatory bowel disease.12 
In mouse experiments, E. faecalis that could produce bacteriophage 
had a competitive advantage against a related strain.18 Presumably, the 
virus it produced could infect and kill the competing strain. However, 
other evidence suggests that most of the bacteriophage in the human 
gut is of the temperate type which does not lyze its targets, and thus 
bacteriophage “predation” may not play a significant role in the gut 
ecosystem as in other environments.16,19 Like bacteriocins, bacterio-
phages usually have a very narrow target range. Although they have 
been used therapeutically for this very reason,20 the extent of their 
role in colonization resistance is uncertain.
The type VI secretion system (T6SS) is a protein translocation com-
plex found in some Gram- negative bacteria, which shares mechanistic 
similarities to some bacteriophage proteins. It is used by bacteria to 
transfer effector proteins into other bacterial or eukaryotic cells.21 
Recently, a new family of T6SS proteins was found in members of the 
Bacteroidetes phylum,22 which along with the Firmicutes dominates 
mammalian guts. The presence of a T6SS and its associated effectors 
and immunity proteins was shown in several studies to have a major 
role in the competition between Bacteroides species inhabiting the 
mouse gut.22–24 Importantly, T6SS- mediated competition is contact- 
dependent, can involve diverse combinations of effector and immu-
nity proteins, and can have a broader target range than other killing 
mechanisms.
2.3 | Inhibitory metabolites
Metabolic byproducts produced by bacteria can also have an inhibi-
tory effect on other bacteria. Short- chain fatty acids (SCFAs: e.g. ace-
tic, propionic, and butyric acid) were identified early on as a key factor 
in the inhibition of S. Typhimurium growth in the mouse25 and are also 
active against pathogenic E. coli26,27 and Clostridium difficile.28 They 
are produced by anaerobic symbiotic bacteria such as the Bacteroides 
and Clostridia, which are abundant members of the adult mammalian 
microbiota. Clostridia species in particular are able to protect mice 
from S. Typhimurium and C. rodentium, through unknown mechanisms 
that may include production of inhibitory compounds.29 Importantly, 
SCFAs require acidic pH for their suppressive activity, a condition 
which is also maintained by the normal bacteria.30 SCFAs can also 
affect pathogen virulence; for example, propionate and butyrate can 
suppress S. Typhimurium virulence factors, while acetate and formate 
have the opposite effect.31–33 SCFAs can also act on the host, causing 
it to lower oxygen concentrations and creating a less favorable envi-
ronment for pathogen growth.34
Bile acids are amphipathic, cholesterol- derived molecules se-
creted into the small intestine. Their main function is to emulsify 
fat and fat- soluble vitamins for absorption, but they also have anti-
bacterial properties. Bile acids are usually secreted and conjugated 
to taurine or glycine, which increases their solubility. A variety of gut 
bacteria produce bile salt hydrolase enzymes that remove the conju-
gated molecule.35 This may be done to reduce the bile acid’s solubility 
and hence toxicity, or to obtain the taurine or glycine. The deconju-
gated primary bile acids can be further converted to secondary bile 
acids by 7α- dehydroxylation. A much more restricted set of bacteria, 
mostly Clostridia, have this ability.35 Buffie et al.36 correlated bacterial 
species with protection from C. difficile infection in antibiotic- treated 
mice and humans, and identified Clostridium scindens as a good predic-
tor of resistance. C. scindens is capable of creating secondary bile acids 
by 7α- dehydroxylation that can inhibit C. difficile growth. C. scindens 
was able to protect mice from C. difficile, as well as restoring second-
ary bile acid levels. Using metabolomic analysis of resistant or sus-
ceptible mice, Theriot et al.37 similarly found a correlation between 
the secondary bile acid deoxycholic acid and resistance to C. difficile. 
Interestingly, the primary bile acid chenodeoxycholic acid can also 
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have an indirect protective function by activating innate defenses in 
the small intestine via its receptor, FXR.38
2.4 | Competition for nutrients and space
Freter proposed the “nutrient niche” hypothesis in 1983, stating that 
“the populations of most indigenous intestinal bacteria are controlled 
by one or a few nutritional substrates which a given strain can uti-
lize most efficiently”.39 Subsequent experiments supported the idea 
that for some bacteria, substrate limitation was indeed an important 
determinant of their successful colonization of the gut.40,41 In E. coli, 
for instance, the ability to utilize one sugar changed the competitive 
balance between otherwise identical strains in the gut.42 Using an 
elegant genetic screen, Lee et al.43 identified a genetic locus, likely 
related to host glycan utilization, which controls intraspecies competi-
tion among gut Bacteroides. Maldonado- Gomez et al.44 examined the 
metagenomes (sequences of all bacterial genes in the gut) of human 
subjects to understand why a probiotic strain of Bifidobacteria could 
sometimes establish itself permanently (instead of transiently coloniz-
ing like most probiotics). They found that the availability of an open 
functional niche involving carbohydrate utilization may be an impor-
tant factor.
Carbohydrate sources are present in ingested food and on host 
cells and secreted mucus. Gut symbionts, especially the Bacteroides, 
possess many genes that enable the digestion of complex polysac-
charides, which the host and other bacteria cannot access. Ng et al.45 
found that sialic acid and fucose, liberated from host glycans by sym-
bionts like Bacteroides species, were an important sugar source for 
invading S. Typhimurium and C. difficile. Crucially, these sugars only 
became available to the pathogens when the bacteria that normally 
consume them were depleted by streptomycin. Similarly, the metab-
olite succinate, produced by Bacteroides species, became available in 
the gut after antibiotic treatment, and this promoted C. difficile coloni-
zation.46 To effect clearance of Citrobacter rodentium from the mouse 
gut, the microbiota acts in concert with the host immune system,47,48 
and competition for sugars appears to play an important role here as 
well. Once host IgG has targeted virulence factor- expressing C. roden-
tium and excluded them from the epithelial surface they must com-
pete with symbionts in the gut lumen.48 Here, they are outcompeted 
by a native E. coli species, but not by Bacteroides species, since these 
presumably prefer other sources of food (such as complex polysac-
charides). However, when the diet is changed to one low in polysac-
charides but high in simple sugars, Bacteroides now compete with and 
reduce the numbers of C. rodentium.47 This is an important reminder 
that diet can have a profound impact on the available nutrients, and 
the structure, activity, and function of the gut microbes.49–51 Microbes 
can also modify the other major source of sugars in the gut: host gly-
cans. This will be addressed in the following section on indirect mech-
anisms of resistance.
Iron is another important nutrient for bacteria and it is tightly se-
questered by the host, especially during inflammation. Competition 
for iron might be another explanation for E. coli Nissle’s ability to re-
duce S. Typhimurium colonization in mice.52
While the nutrient niche concept has been validated in several 
cases, untangling the extremely complex metabolic interactions in the 
gut ecosystem remains a daunting challenge.
2.5 | Physical niches
In addition to functional nutrient- based niches, bacteria must com-
pete for physical space. Some species prefer living on the food mat-
ter in the lumen, or in the outer mucus layer, or more rarely at the 
epithelial surface. Close physical contact with the epithelium is an 
essential part of some pathogens’ lifestyles (e.g. C. rodentium, some 
pathogenic E. coli, S. Typhimurium), so physical competition for adhe-
sion sites (often glycan structures) could prevent infection or pathol-
ogy.53 Interestingly, microbes can also change the presence of host 
adhesion sites indirectly (see below).
2.6 | Indirect mechanisms of colonization resistance
Aside from direct competition, microbes can compete with one an-
other indirectly by acting on the host. This usually involves stimula-
tion of the innate or adaptive immune system, but other non- immune 
defenses can also take part. Microbial stimulation of the host immune 
system will be explored in detail in Sections 3-5, below. Here, we will 
focus on non- immune factors stimulated by the microbiota that can 
affect colonization resistance.
2.7 | Mucus and glycosylation
The mucus layers in the small intestine, cecum, and colon are a crucial 
part of the epithelial defenses, and are stimulated by the presence of 
the microbiota.54 In the cecum and colon, the inner, firmly attached 
mucus layer effectively excludes bacteria and particles of similar size, 
but not in GF mice.55 The large intestine mucus’ main component is 
the glycoprotein Muc2, but it also contains other proteins that can im-
mobilize or kill bacteria.56,57 Mice lacking Muc2 have higher pathogen 
loads and more intestinal damage when infected with C. rodentium.58 
Likewise, S. Typhimurium growth in the cecum and translocation to 
the liver is greater in the absence of Muc2.59
Muc2 is heavily glycosylated. Glycosylation of the intestinal 
mucus and epithelium is quite complex and can change in response to 
microbial colonization.60 This is interesting because host glycans can 
serve as nutrient sources or adhesion receptors for microbes, includ-
ing pathogens. One glycosylation modification, α(1,2)fucosylation, is 
especially intriguing. It is stimulated in the ileal epithelium and mucus 
of mice by commensal or mutualistic bacteria,61 and may be a useful 
sugar source for some.62 α(1,2)fucosylation is also robustly activated 
throughout the small intestine during infection, via MyD88 and IL- 22 
signaling.63,64 This supply of fucose during sickness may help pacify 
dangerous bacteria as well as feeding symbionts: fucose suppresses 
virulence genes in pathogenic E. coli as well as in members of the 
normal microbiota.63,65 Fucosylation also reduces pathology caused 
by C. rodentium, and prevents an opportunistic pathogen (E. faeca-
lis) from escaping the gut and causing disease.66 Microbes may also 
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affect host modification of free sugars in the gut. Faber et al.67 found 
that treating mice with streptomycin led to increased levels of two 
oxidized sugars, galactarate and glucarate, in the cecal lumen. These 
sugars are formed from galactose and glucose by the host’s induc-
ible nitric oxide synthase enzyme (iNOS), and iNOS expression was 
increased after streptomycin treatment. Streptomycin may directly 
trigger iNOS, or it may kill symbionts which normally suppress iNOS 
and/or consume the oxidized sugars. In either case, the greater avail-
ability of these sugars after antibiotic treatment fed S. Typhimurium 
growth.67
3  | REGULATION OF MYELOID CELLS 
BY THE GUT MICROBIOTA
The intestinal immune system is immensely shaped by the gut mi-
crobiota. Myeloid cells such as neutrophils and macrophages are 
typically the first immune responders to an infection. Although 
myelopoiesis occurs in the bone marrow, a broad effect of the gut 
microbiota on bone marrow hematopoiesis and the functions of 
intestinal macrophages have been implicated by multiple studies 
(Figure 2).
F IGURE  2 Effects of the gut microbiota on host immune responses. Through TLRs, molecules from gut symbiotic bacteria promote 
granulopoiesis of neutrophils in the bone marrow and mobilization of neutrophils upon infection. The presence of gut symbiotic bacteria is 
important for expression of pro- IL- 1β in intestinal macrophages, which can be cleaved to mature IL- 1β by selective gut Enterobacterial symbionts 
via NLRP3 inflammation during gut injury to promote proper inflammatory response. IL- 1β, IL- 23, and IL- 6 from intestinal macrophages are 
important to promote mucosal Th17 cell response, and IL- 10 from intestinal macrophages as well as microbial short- chain fatty acids (SCFAs) 
are involved in the development of Tregs in the gut under homeostatic conditions. The presence of the gut microbiota is critical for induction 
of both T cell- dependent and independent production of IgA antibodies, most of which are specific for gut symbionts and are transferred to 
intestinal lumen where they target invading bacteria to prevent them from crossing the epithelial barrier. During enteric Citrobacter rodentium 
or Clostridium difficile infection, IL- 22, mostly produced by ILC3 cells, can act systemically to induce hepatocytes to produce hemopexin and 
complement C3, respectively, to inhibit the growth and clearance of systemically translocated bacteria. Under homeostatic conditions, selective 
members of Gram- negative gut symbionts induce systemic production of IgG antibodies that can recognize bacterial surface antigens, such as 
murein lipoprotein (MLP) that are expressed on some Gram- negative pathogens, thereby contributing to host defense against systemic infection 
by gut symbionts or pathogens
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3.1 | Neutrophils
Mice treated with broad- spectrum antibiotics were shown to have a 
decrease in the numbers of stem cells and progenitors in the bone 
marrow.68 Khosravi et al.69 reported innate immune defects in GF 
mice as a result of the absence of the gut microbiota, which leads to 
impaired early immune responses to pathogens, and recolonization of 
GF mice with a complex microbiota restores defects in myelopoie-
sis and resistance to systemic infection with Listeria monocytogenes. 
Mechanistically, microbial molecules such as lipopolysaccharides were 
shown to sustain steady- state production of neutrophils and priming 
of neutrophils against bacterial infections through Toll- like receptor 
signaling.70,71 In addition, intestinal ILC3 production of IL- 17 induced 
by the gut microbiota leads to G- CSF- mediated granulopoiesis in the 
bone marrow, which was critical to combat E. coli sepsis in neonatal 
mice.72 On the other hand, microbiota- mediated priming/activation 
of neutrophils has been shown to increase the number of activated/
aged neutrophils in the circulation, which secrete pro- inflammatory 
cytokines and granule proteases that damage tissues and exacerbate 
disease. In mouse models of sickle- cell disease and endotoxin- induced 
sepsis, depletion of the gut microbiota significantly reduced the num-
ber of circulating aged neutrophils and lessened organ damage.73 We 
previously reported that during systemic E. coli infection, microbial 
ligands including those from the microbiota induce NOD1 and TLR4 
signaling to mobilize myeloid progenitors to the spleen where these 
mobilized progenitors mature into neutrophils to combat the infec-
tion.74 It is possible that gut microbiota- derived ligands play similar 
roles in homeostatic mobilization of myeloid progenitors to various 
organs where they give rise to mature myeloid cells for maintenance 
of tissue homeostasis. Taken together, microbial molecules from the 
gut microbiota appear to have a profound and sustained effect on 
neutrophils, from granulopoiesis of myeloid progenitors in the bone 
marrow to the response of mature neutrophils to infection and ulti-
mately aging of mobilized neutrophils.
3.2 | Intestinal eosinophils
Eosinophils constitute a major population of leukocytes in the gastro-
intestinal tract under homeostatic conditions, independently of the gut 
microbiota.75,76 Although eosinophils are most known as proinflamma-
tory cells that contribute to the pathogenesis of various allergic dis-
eases, more recent studies reveal remarkable functional diversity of 
eosinophils in different tissues.77 For example, unlike eosinophils from 
the lung or blood, small intestinal eosinophils display extended lifes-
pans.75,76 Sugawara et al.76 recently reported that small intestinal eo-
sinophils constitutively secrete high levels of IL- 1 receptor antagonist 
(IL- 1Ra), a natural inhibitor of IL- 1β, which is promoted by production 
of GM- CSF by intestinal epithelial cells in a gut microbiota- independent 
manner. By suppressing the levels of IL- 1β in the small intestine, eosin-
ophils suppress Th17 cells, thereby playing a critical role in the mainte-
nance of intestinal homeostasis. The function of this major leukocyte 
population in the gut, however, has not been extensively explored, ei-
ther in the steady state or in the context of food allergies.
3.3 | Intestinal macrophages
There are resident macrophages in every tissue of the body, where 
they contribute to the maintenance of tissue by acting as the first 
line of defense against pathogens and by initiating wound repair.78 
A recent study demonstrated that yolk sac and fetal liver- derived 
macrophages are present in the neonatal intestine, which however 
are diluted by Ly6Chi monocyte- derived macrophages that infiltrate 
into the intestine around the time of weaning, in a process that is 
dependent on CCR2 expression of the monocytes and neonatal gut 
microbiota.79 Consistently, although GF mice exhibit a normal intes-
tinal macrophage compartment at birth, recruitment of Ly6Chi mono-
cytes into the intestine is markedly diminished at 3 weeks of age.79 
Intestinal macrophages are hyporesponsive to bacterial Toll- like re-
ceptor ligands such as lipopolysaccharides, which is critical to prevent 
inappropriate activation of inflammatory responses in the intes-
tine.80,81 Consistently, we have previously demonstrated that a lack of 
a functional NLRP3 inflammasome in intestinal resident macrophages, 
which would minimize inappropriate production of IL- 1β and induction 
of inflammation under steady- state conditions.82 On the other hand, 
intestinal macrophages constitutively express NLRC4 and pro- IL- 1- β, 
which allows precipitous release of IL- β and initiation of inflammatory 
response upon infection with enteric pathogens, such as Salmonella. 
Our studies also revealed that constitutive expression of pro- IL- 1- β 
requires the gut microbiota in a Myd88- dependent manner.82,83 In ad-
dition, in response to intestinal injury, our more recent study showed 
that gut symbiotic Enterobacteriaceae, and in particular Proteus mira-
bilis, induce robust NLRP3 inflammasome- mediated IL- 1β production 
in newly recruited Ly6Chi monocytes, which promotes inflammation 
in the intestine.84 Taken together, our studies and others’ suggest a 
complex role for the gut microbiota in controlling recruitment of cir-
culating monocytes to replenish resident intestinal macrophages and 
functional changes of intestinal macrophages in response to injury or 
infection.
4  | REGULATION OF T- CELL RESPONSE 
BY THE GUT MICROBIOTA
A myriad of intestinal immune defects are observed in GF animals, 
including impaired development of gut- associated lymphoid tissues 
(GALTs), gut- associated Th17 cells and Tregs, lower numbers of IgA- 
producing B cells and intraepithelial CD8+ T cells (Figure 2).
4.1 | Th17 cells
GF mice have reduced numbers of Th1 and Th17 cells. Th17 cells are 
a subset of CD4+ effector T cells that make copious amounts of IL- 17, 
which plays important roles in host defense against extracellular path-
ogens as well as the development of autoimmune diseases.85 Studies 
have demonstrated that development of Th17 cells in the small intes-
tine can be potently induced by colonization of commensal Clostridia- 
related segmented filamentous bacteria (SFB),86–88 and to a lesser 
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extent by colonization of altered Schaedler flora (ASF), a cocktail of 
eight defined commensals.89 Two more recent studies elucidated a 
cascade of events initiated by SFB adhesion to the small intestine 
epithelium to promote IL- 17 expression in RORγt+ CD4+ T cells in 
the gut. Enhanced SFB adhesion on the epithelial induces the expres-
sion and release of serum amyloid A (SAA) from intestinal epithelial 
cells (IECs), and SAA potentiates the production of IL- 1β and IL- 23 in 
CX3CR1+ phagocytes, two cytokines that synergistically promote the 
production of IL- 22 in ILC3. IL- 22, in turn, reinforces SAA- mediated 
IL- 1β production by phagocytes, which ultimately upregulates IL- 17 
production in RORgt+ CD4+ T cells.90,91 It remains unclear what dis-
tinct signals from bound SFB are critical for the release of SAA from 
IECs, and whether this IL- 17- inducing mechanism is unique to SFB or 
all symbiotic bacteria with IEC- adhesive characteristics. Interestingly, 
the ability of gut symbiotic bacteria to elicit Th17 response could be 
potentially exploited in the context of anti- tumor immunity. A previ-
ous study showed that treatment of cyclophosphamide, a commonly 
used cancer drug known to stimulate anti- tumor immune response, 
alters the composition of the gut microbiota in the small intestine and 
induces translocation of selective Gram- positive bacteria to second-
ary lymphoid organs. These translocated bacteria stimulate the gener-
ation of “anti- tumor” Th17 cells that are important for the therapeutic 
efficacy of cyclophosphamide.92 Therefore, knowledge of the link be-
tween symbiotic bacteria and induction Th17 cells can be harnessed in 
addressing diseases that involve aberrant Th17 response.
4.2 | Tregs
In the absence of the gut microbiota, the number of inducible Foxp3 
Helio- Tregs (iTregs) is specifically reduced in colonic lamina propria, 
but unaffected in the small intestine or mesenteric lymph nodes.93 
Treg- inducing activity in mice was found in a cocktail of 46 strains of 
the Clostridium genus belonging to clusters IV and XIVa (also known 
as the Clostridium leptum and Clostridium coccoides groups, respec-
tively), and in ASF consisting of three Clostridia species belonging to 
the Clostridium cluster XIV. A cocktail of 17 human Clostridia strains 
was also identified to possess Treg- inducing activity. Moreover, 
colonization of Bacteroides fragilis, a human species, was shown to 
induce Tregs and production of IL- 10 by polysaccharide A via TLR2 
signaling.94,95 In addition, bacterial metabolites short- chain fatty acids 
(SCFAs), which are at reduced levels in the colonic lumen of GF mice, 
have been shown to regulate the development and function of colonic 
Tregs.93,96,97 SCFAs, particularly butyrate, can directly enhance acety-
lation of the Foxp3 locus in Tregs.96,97 In a study of GF mice colonized 
with 17 human Clostridium strains, luminal levels of SCFAs acetate, 
propionate, isobutyrate, and butyrate were elevated to promote TGFβ 
production in colonic epithelial cells, which indirectly contributes to 
the development of colonic Tregs.91 The receptors that are activated 
by SCFAs, namely several G- protein- coupled receptors (GPRs) such 
as GPR43, are expressed on both IECs and most hematopoietic cells. 
Consistently, mice lacking GPR43 have lower numbers of Tregs. It 
should be noted that the effect of SCFAs on the induction of Tregs 
appears not restricted to the colon, as studies have shown histone 
deacetylase (HDAC) inhibitory activity of butyrate that regulates LPS- 
responsive genes (e.g. Il2, Il6, and RelB) in DCs to promote the dif-
ferentiation of Tregs. This appears to be a common mechanism that 
regulates the generation of extrathymic Tregs. Hence, the systemic 
effect of SCFAs on the induction of Tregs is not consistent with the 
colon- specific defect in Treg development in GF mice. This suggests 
that there might be redundant SCFA- independent mechanisms to 
promote the development of Tregs in most tissues, which however 
might be lacking in the colon.
4.3 | ILC3
Innate lymphoid cells (ILCs) are a population of innate immune cells 
that differentiate independently of somatic recombination or inter-
actions with cognate antigens presented by MHCII, but exhibit a cy-
tokine profile akin to that of CD4+ T cells. ILCs are found at barrier 
surfaces of the mammalian body, such as the skin, airway, and the 
gastrointestinal tract. Three distinct groups of ILCs have emerged, 
based on their cytokine profiles: Tbet+ Group1 ILCs (IFNγ producers), 
GATA3+ Group2 ILCs (IL- 4, IL- 13 and IL- 9 producers), and RORγt+ 
ILCs Group 3 (IL- 22 and IL- 17 producers).98 There is increasing evi-
dence supporting an important role for ILC3 in intestinal immunity. 
For example, IL- 22 produced by ILC3 promotes production and se-
cretion of RegIIIg, a secretory antimicrobial peptide by intestinal epi-
thelial cells that has been shown to be critical in enteric infection by 
Citrobacter rodentium.99–101 There have been conflicting reports on 
whether the development of ILC3 requires gut symbiotic bacteria, 
with several studies showing normal development of RORγt+ ILCs in 
both GF mice and antibiotic- treated mice, and other studies revealing 
the lack of RORγt and IL- 22 expression in the small intestine of in 
both GF mice and antibiotic- treated mice. The discrepancy might at-
tribute to diet- derived microbial signals that GF mice in these studies 
could have been potentially exposed to.98 Nonetheless, gut symbiotic 
bacteria are believed to influence the function of ILC3, either by di-
rectly signaling through pattern- recognition receptors (PRR) on ILC3 
or by indirectly regulating intestinal myeloid cells and epithelial cells. 
Human RORγt+ ILCs were shown to express functional TLR2, which 
can be stimulated to induce IL- 2 that enhances IL- 22 production in 
an autocrine manner.102 The Aryl hydrocarbon receptor (AhR), which 
can be activated by ligands generated from tryptophan metabolism 
by gut symbiotic bacteria, is expressed on RORγt+ ILCs and critical for 
ILC development, IL- 22 production, maturation of GALTs, and enteric 
immunity against Citrobacter rodentium.99–101 In addition, IL- 1β and 
IL- 23 produced by intestinal phagocytes can promote IL- 22 produc-
tion RORγt+ ILCs.103 We have previously shown that gut symbiotic 
bacteria promote the expression of IL- 1β in intestinal macrophages 
under steady- state conditions that likely contribute to the emergence 
of RORγt+ ILCs.83
Furthermore, the role of RORγt+ ILCs in regulating the gut micro-
biota has been unraveled in recent studies. RORγt+ ILC production of 
lymphotoxin (LTα1β2) promotes the generation of isolated lymphoid 
follicles (ILFs), which are critical for T cell- independent intestinal IgA 
production.104,105 RORγt+ ILCs are also major producers of IL- 22, 
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which promotes epithelial cells production of mucins and antimicro-
bial proteins (RegIIIb, RegIIIg, S100A8, and S100A9), which are integral 
for compartmentalization of gut bacteria within the gastrointestinal 
tract.106 The importance of intestinally induced ILC3 in mediating sys-
temic host defense against systemic infection, mainly via IL- 22, has 
been highlighted in our recent studies. We showed that in enteric 
Clostridium difficile infection (CDI), IL- 22, which was shown in a sep-
arate study to be produced mainly by ILC3 in CDI,107 can act systemi-
cally on hepatocytes that express IL- 22R.108 As a result, IL- 22 induces 
production of complement C3 from hepatocytes, which promotes 
clearance of systemically translocated gut bacteria following CDI and 
thereby confers protection.108 In addition, our recent study showed 
that during enteric C. rodentium infection, IL- 22 produced by ILC3 
systemically induces the production of heme scavenger hemopexin 
to limit heme availability and thereby suppress the growth of bacte-
ria that have translocated systemically due to damaged gut epithe-
lial barrier.109 Furthermore, Hepworth et al.110 reported that MHCII+ 
ILC3 cells directly kill CD4+ T cells that are reactive to gut symbiotic 
bacteria, in a manner reminiscent of how self- reactive T cells are elim-
inated in the thymus. Notably, MHCII on colonic ILC3 was reduced 
in pediatric IBD patients, suggesting possible impairment in MHCII+ 
colonic ILC3 to dampen self- reactive CD4+ T cells in IBD. Collectively, 
these studies support a beneficial role for gut ILC3 in both intestinal 
and systemic host defense against pathogens or pathobionts as well 
as dampening otherwise deleterious T- cell response to gut symbiotic 
bacteria, thereby maintaining tissue homeostasis in the intestine.
5  | REGULATION OF B- CELL IMMUNE 
RESPONSE BY THE GUT MICROBIOTA
The gut is home to at least 80% of all activated plasmablasts and plasma 
cells, most of which produce IgA.111 Primary B- cell development, 
which in humans and mice involves Rag- dependent V(D)J recombina-
tion for pre- immune diversification, is thought to occur exclusively in 
the bone marrow. However, recent evidence suggests a critical role 
for the gut microbiota during early life in B- cell selection and pre- 
immune immunoglobulin diversification. Using a Rag2- GFP reporter 
mouse model, Alt and colleagues showed that Rag2+CD19+B220low 
cells, which are undergoing active V(D)J recombination, are almost 
undetectable in the first week after birth, emerge and expand rapidly 
at weaning age (18- 24 days), and wane at about 5- 6 weeks of age.112 
Of note, the gut microbiota expands quickly upon weaning, suggesting 
a possible role for maternal immunoglobulins in restricting expansion 
of the gut microbiota prior to weaning before the neonatal immune 
system is fully developed. Consistently, conventionalization of GF 
mice increases the levels of pro- B cells systemically and in the gut LP. 
The transient nature of LP B- cell development upon weaning might 
be a window for both luminal antigens to shape pre- immune B- cell 
repertoire. The study by Alt and colleagues also revealed similar VH 
repertoires but markedly different V repertoires of LP and BM Rag2+ 
B cells, reflecting differential BCR editing within the gut and BM, re-
spectively. BCR editing in the BM is a negative selection to eliminate 
self- reactive B cells, but it remains unclear whether BCR editing in the 
gut also serves as a similar tolerance mechanism.
5.1 | IgA
IgA is the most abundant isotype of antibodies that can be readily 
secreted into the lumen of the gut under steady- state conditions. 
Polymeric IgA binds to the polymeric immunoglobulin receptor 
(pIgR) expressed on the basolateral surface of the gut epithelium, 
which transports IgA to the apical surface. IgA is released in the gut 
lumen upon proteolytic cleavage of the secretory component of pIgR. 
Mucosal IgA- secreting cells are markedly reduced in GF mice and 
undetectable in the neonatal gut prior to colonization of symbiotic 
bacteria, hence suggesting that gut symbiotic bacteria might provide 
key stimulatory signals to induce production of mucosal IgA. A previ-
ous study showed that, during pregnancy in GF female mice transient 
inoculation of a mutant E. coli strain (HA107), which was engineered 
to allow reversible and transient colonization of GF mice, was suf-
ficient to induce robust and specific IgA response in the offspring. A 
potent stimulatory effect on induction of IgA response was observed 
upon colonization of SFB in GF mice.113 Notably, SFB colonization 
is associated with induction of Th17 cells, which have been shown 
to expand and home to the small intestine in mice monocolonized 
with SFB. In the Peyer’s patches of these mice, Th17 cells acquire a 
phenotype reminiscent of T follicular helper (TFH) cells to induce the 
development of IgA- producing germinal center B cells. Consistently, 
mice lacking Th17 cells are impaired in mounting antigen- specific 
IgA response after immunization with cholera toxin, thus underscor-
ing an indispensible role for Th17 cells in T cell- dependent genera-
tion of antigen- specific IgA antibodies.114 It remains unclear however 
whether IgA response is induced only by selective members of gut 
symbiotic bacteria.
The function of IgA in host- microbe symbiosis as well as in host 
defense has been extensively studied but to an extent remains un-
defined, given that IgA deficiency is the most common primary im-
munodeficiency and most affected individuals are asymptomatic.115 
It is likely that IgA deficiency can be compensated by other immune 
mechanisms, such as increased export of SIgM, which is facilitated by 
pIgR as well. In mice, most intestinal IgA is directed against gut symbi-
otic bacteria, and coating by SIgA in intestinal lumen prevents invading 
bacteria from crossing the gut epithelium.116 Studies of mice deficient 
in pIgR showed impaired export of SIgA and SIgM into the intestinal 
lumen, elevated serum IgG, and more importantly, increased mucosal 
penetration of symbiotic bacteria and enhanced systemic antibodies 
against these translocated bacteria. Macpherson and colleagues re-
ported that IgA restricts penetration of gut symbiotic bacteria to the 
mesenteric lymph nodes, thereby limiting systemic dissemination of 
symbiotic bacteria and preserving host- microbe symbiosis.117,118 
Consistently, a recent study demonstrated that intestinal bacteria with 
high IgA coating confer enhanced susceptibility to DSS- induced colitis 
in GF mice, suggesting that IgA specifically coats more inflammatory 
and hence colitogenic intestinal bacteria under homeostatic conditions 
to confine these harmful bacteria in the intestinal lumen.119 Together, 
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these studies highlight an integral role for IgA in compartmentalizing 
intestinal bacteria, especially those with heightened virulence, in the 
intestinal lumen to maintain host- microbe symbiosis.
5.2 | IgE
IgE antibodies play a critical role in allergies, asthma, and immunity 
to parasites,120 and studies of human infants and animal models sup-
port a role for mucosal microbiota in asthma and atopic disease de-
velopment.121–123 IgE production appears to be heavily influenced by 
the gut microbiota as well, albeit by a mechanism seemingly opposite 
to that underlying gut microbiota- regulated IgA response. Cahenzli 
et al.124 reported profoundly high levels of IgE are produced in GF 
mice immediately after weaning, due to active CD4+ T cell- dependent 
B- cell isotype switch to IgE at mucosal sites, particularly Peyer’s 
patches, in the absence of microbial exposure. Colonization of GF 
mice with diverse microbiota, but not specific symbiotic bacteria, from 
birth to 4 weeks of age but not thereafter normalizes the IgE levels in 
adults,124 suggesting that diverse microbial exposure at mucosal sites, 
while triggering IgA isotype switch, downregulates IgE to baseline lev-
els. The age- specific effect of the gut microbiota to tone down IgE 
response is intriguing, but the underlying mechanisms remain largely 
elusive. These studies underscore infancy as a critical window of op-
portunity for the gut microbiota to educate the host immune system 
and provide long- term benefits.
5.3 | IgG
In contrast to IgA, which is locally induced in GALTs by gut symbiotic 
bacteria, induction of high- affinity, antigen- specific IgG antibodies is 
thought to take place in extra- intestinal organs, such as the spleen. 
However, redundant measures are in place to ensure compartmen-
talization of symbiotic bacteria in the intestine, including sIgA, patrol-
ling intestinal phagocytes, mucous layer, the epithelium, and lastly 
the MLNs as a firewall where escaped intestinal bacteria would be 
killed by phagocytes. For years, there was the dogma of systemic ig-
norance, rather than tolerance, toward intestinal symbiotic bacteria 
due to complete compartmentalization of intestinal symbiotic bacteria 
in the intestine. This dogma was supported by a study showing un-
detectable serum IgG from naive mice against Enterobacter cloacea, a 
Gram- positive gut symbiotic bacterium.125 However, higher titers of 
serum IgG against fecal symbiotic bacteria were frequently reported 
in patients with either Crohn’s disease or Colitis, which was thought to 
reflect either prior infections or systemic translocation of gut bacteria 
in these patients due to “leaky” epithelial barrier.126 In addition, we 
recently reported that gut symbiotic bacteria promote the adjuvant 
activity of cholera toxin, an enterotoxin secreted by Vibrio cholera that 
has been used as a potent mucosal adjuvant, through Nod2- mediated 
recognition of its microbial agonist by dendritic cells.127
Evidence from a few recent studies has emerged that the systemic 
immune system in humans and mice is not ignorant toward gut sym-
biotic bacteria under homeostatic conditions. We recently reported 
that in unmanipulated mice and healthy humans, robust levels of 
serum IgG antibodies were detected that selectively recognized pro-
teins from Gram- negative but not Gram- positive symbiotic bacteria128 
(Figure 2). Consistently, bacterial DNA was detected in the spleens of 
naive mice, suggesting some gut symbiotic bacteria likely had made 
their way to extra- intestinal organs to initiate systemic immune re-
sponses, including generation of antigen- specific IgG. This suggests 
that in the steady state perhaps a small number of Gram- negative 
Enterobacterial species, which have been shown to possess unique 
growth advantages that enable them to bloom in an inflamed gut,129 
may be uniquely equipped for successful penetration of the gut epi-
thelial barrier, evasion of killing by phagocytes in the mesenteric lymph 
nodes, and induction of systemic response. Our data also illustrated 
the requirement for CD4+ T cells and TLR4 on B cells for induction 
of homeostatic generation of antigen- specific IgG antibodies to gut 
symbiotic bacteria.
Furthermore, we identified murein lipoprotein (MLP), a secretary 
outer membrane protein abundantly expressed on Gram- negative 
Enterobacterial species, as a major bacterial antigen recognized by 
serum IgG in naive mice and healthy humans. Bacteremia due to 
Gram- negative symbiotic bacilli, most commonly E. coli, accounts for 
25%- 50% of all bloodstream infections. Therefore, the potential of ho-
meostatically induced serum anti- MLP IgG, and other still unknown 
IgG against gut microbiota- derived antigens, should be further investi-
gated for the treatment of Gram- negative sepsis.
Low concentrations of symbiotic bacteria- specific IgG in younger 
mice from our study, and very likely in human infants and toddlers, 
might contribute to increased susceptibility of neonates to infection. 
Maternal IgG antibodies are transported to the infant, through the 
placenta or breast milk, to provide crucial passive immunity in the de-
veloping fetus or infant, respectively. Consistently, a recent study by 
Koch et al.130 showed that maternal IgG and IgA antibodies in neonatal 
mice dampen mucosal T follicular helper responses and subsequent 
germinal center B- cell responses following birth. Our studies high-
light the importance of developing proper homeostatic IgG antibodies 
against conserved bacterial antigens that may confer critical protec-
tion against pathogens later in life. In light of this, excessive use of 
antibiotics in young children might potentially delay or impair proper 
development of IgG response and immune memory against symbiotic 
and pathogenic bacteria and have a profound impact on later life. 
Therefore, our results underscore the importance of having a balanced 
microbial community in the intestine in early life, as well as the bene-
fits of maternal antibodies for neonatal health.
6  | EFFECTS OF INFLAMMATION 
ON THE COMMUNITY STRUCTURE OF THE 
GUT MICROBIOTA
6.1 | Selection of symbiotic bacteria that thrive in 
the inflamed gut
The composition of the human large bowel microbiota exhibits great 
intersubject variability.131 Nevertheless, there are some conserved 
features that define a balanced gut microbiota, including a prominent 
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representation of members of the Firmicutes and Bacteroidetes phyla and 
a lower abundance of members of the Proteobacteria, Actinobacteria, 
Fusobacteria, and Verrucomicrobia phyla.131 Intestinal inflammation can 
lead to an altered composition of gut microbiota, known as dysbiosis, 
that is associated with functional changes in the microbial transcrip-
tome, proteome or metabolome.132–134 Growing evidence has shown 
that perturbation of the gut microbial community may fuel blooms of 
otherwise low abundance and harmful bacteria which can further exac-
erbate the intestinal inflammation. Indeed, dysbiosis in the distal gut is 
often characterized by a decrease in the prevalence of strict anaerobes 
and an increased relative abundance of facultative anaerobic bacte-
ria.135,136 In particular, expansion of Enterobacteriaceae is commonly 
observed in gut dysbiosis in a variety of contexts involving intestinal in-
flammation.135–141 Enterobacteriaceae, a large family of Gram- negative 
facultative anaerobes that belongs to the class of Gammaproteobacteria 
and to the phylum Proteobacteria, are usually localized in close prox-
imity to the gut epithelium due to their relative high tolerance to the 
oxygen that diffuse from the epithelial barrier. While elevated oxy-
gen levels increase the relative abundance of Enterobacteriaceae, the 
limited amount of available oxygen in the colon contributes to their 
low prevalence. Indeed, Enterobacteriaceae represent a small frac-
tion, roughly 0.1%, of the microbial community in the distal gut.131 
Interestingly, Enterobacteriaceae are among the most commonly symbi-
onts that overgrow in various settings of gut inflammation, such as IBD, 
celiac disease, and colon cancer.137,139,140 Inflammation- induced envi-
ronmental and nutritional changes may confer a growth advantage to 
Enterobacteriaceae. Gut inflammation, that arises after an infection by 
a pathogen, chemically induce colitis or host immune deficiency, seems 
to foster the expansion of Enterobacteriaceae by providing a favorable 
environment for their growth.128,135,142
An increased prevalence of Enterobacteriaceae, including adher-
ent invasive Escherichia coli (AIEC), has been observed in patients 
with Crohn’s disease (CD) and ulcerative colitis (UC), the two major 
forms of IBD.139,143–146 Consistently, the relative luminal abundance 
of Enterobacteriaceae dramatically increased in either chemical- 
induced or genetic mouse models of IBD.135,136,142 Despite these as-
sociations, no single pathogens, including AIEC, has been proven to 
cause IBD. On the other hand, the expansion of E. coli seems to be a 
consequence rather than a cause of IBD, most likely due to the ability 
of Enterobacteriaceae to bloom in an inflamed intestinal environment.
Interestingly, two Enterobacteriaceae species, such as Klebsiella 
pneumoniae and Proteus mirabilis, isolated from TRUC mice (i.e. T- 
bet−/− × RAG2−/−) that develop a spontaneous UC- like colitis, can 
elicit colitis in wildtype mice in the presence of endogenous gut mi-
crobiota.142 These observations suggest that inflammation- driven 
expansion of Enterobacteriaceae could potentially contribute to the 
pathogenesis of disease development itself.
Antibiotic treatment has been associated with luminal blooms of 
E. coli and the pathogen C. rodentium, both members of the family of 
Enterobacteriaceae, due to disrupted intestinal homeostasis that results 
in an increased inflammatory tone of the intestinal mucosa in mice.147,148
Similarly, evidence showed that a previous antibiotic use may 
be related to the development of diarrhea- predominant irritable 
bowel syndrome,149,150 a clinical condition in humans characterized 
by increased abundance of Enterobacteriaceae, Pasteurellaceae, and 
Pseudedomonadaceae families (all members of the phylum of 
Proteobacteria).151–154
Furthermore, several reports confirmed a consistent increase in 
the relative abundance of Enterobacteriaceae in the stools of infants 
who developed necrotizing enterocolitis, a fatal disease that is a major 
cause of mortality in preterm infants.155
Intestinal inflammation induced by the administration of en-
teric pathogens or by parasite infection has been associated with 
disruption of the intestinal ecosystem that leads to an uncontrolled 
Enterobacteriaceae expansion within the microbial community inhab-
iting the distal gut.156–158 Notably, it has been shown that pathogens 
belonging to the family of Enterobacteriaceae, namely C. rodentium and 
S. typhimurium utilized virulence factors to promote intestinal inflam-
mation, which in turn conferred a growth advantage for the pathogens 
in the gut lumen.47,156
Finally, expansion of Enterobacteriaceae can negatively affect 
host defense against bacterial pathogens or injury. For example, 
clindamycin- induced expansion of Enterobacteriaceae accounted for 
sustained susceptibility to C. difficile- driven colitis.141 Antibiotic or 
dextran sulfate sodium (DSS) treatment can lead to the expansion and 
extraintestinal dissemination of E. coli pathobionts that result in bacte-
remia, sepsis- like disease, and ultimately mouse death.128,159
In this context, a recent study has identified increased fecal abun-
dance of E. coli and Bacteroides species as an important determinant of 
susceptibility to Campylobacter infection in humans.160
A study on the modulation of gluten- induced immunopathology 
by the microbiota, showed that Proteobacteria expansion caused by 
antibiotic treatment, further enhanced gluten- induced immunopa-
thology in conventional specific pathogen- free (SPF) mice. In addi-
tion, supplementation of SPF microbiota with E. coli, isolated from a 
patient with celiac disease, increased the severity of gluten- induced 
pathology.161 Finally, E. coli and Shigella, isolated from patients with 
celiac disease, have been shown to increase intestinal permeability 
in this intestinal disorder, likely due to reduced expression of tight 
junction proteins.162 Overall, accumulating evidence suggests that 
inflammation- inflicted blooms of Enterobacteriaceae are associated 
with various intestinal diseases and could further exacerbate the in-
testinal inflammation.
6.2 | Selection for expression of bacterial proteins 
that sustain microbial survival and perpetuate 
inflammation
Analyses of bacterial transcriptomes have provided new insights into 
the effects of inflammation on microbial function and the ability to 
survive in the inflammatory environment.
AIEC are able to adhere to ileal enterocytes via the common type 1 
pili adhesin FimH and recognize the carcinoembryonic antigen- related 
cell adhesion molecule 6 (CEACAM6), abnormally expressed on CD 
ileal epithelial cells.163 In this context, FimH DNA sequence analysis 
recently indicated that AIEC strains predominantly expressed FimH 
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with amino acid mutations of a recent origin. These newly generated 
mutations in FimH conferred AIEC a significantly higher ability to ad-
here to CEACAM- expressing intestinal epithelial cells, to persist and 
to induce gut inflammation in a genetically susceptible host.164
In an additional study, analyzing the mutational patterns in the 
FimH gene of mucosa- associated E. coli strains isolated from IBD and 
non- IBD pediatric patients, different FimH mutational patterns have 
been found for each E. coli characteristic (i.e. status, phylogroup, and 
adhesion class). E. coli strains from patients with UC showed increased 
numbers of mutations, while isolates from patients with CD exhibited 
an enhanced mutational rate but different FimH mutations arose.165 
These results suggest that under specific selective pressure, the FimH 
protein undergoes selective amino acid mutations to sustain bacterial 
survival and implies a distinctive behavior adopted by E. coli to survive 
under different inflammatory conditions, such as CD and UC.
Thus, it is conceivable that the inflammatory milieu may select for 
expression of specific microbial proteins that boost bacterial survival 
and further perpetuate inflammation.
6.3 | Mechanisms underlying bacterial blooms in the 
inflamed gut
Several mechanisms responsible for Enterobacteriaceae blooms in 
the inflamed gut have been proposed, including nutritional changes, 
mucin utilization, production of antimicrobials, anaerobic/aerobic res-
piration, and metal utilization (Figure 3).
F IGURE  3 Host- immune interactions play a crucial role in the pathogenesis of Inflammatory Bowel Disease. During homeostasis, gut 
microbiota critically contribute to the development of host intestinal immunity. Beneficial symbionts usually control the expansion of colitogenic 
pathobionts through the induction of regulatory immune responses, involving regulatory T (Treg) cells, interleukin- 10 (IL- 10), and regenerating 
islet- derived protein 3γ (REGIIIγ). In IBD, confluence of environmental and genetics factors may alter the balance between host immune and gut 
microbial factors triggering intestinal inflammation. Environmental factors, such as diet and antibiotic treatment, can disrupt the gut microbial 
community structure. Additionally, variants in NOD2, ATG16L1, and IRGM genes may perturb many aspects of immune homeostasis including 
reduced muramyl- dipeptide sensing in antigen- presenting cells, impaired anti- microbial responses in Paneth cells, and altered intraepithelial 
autophagy leading to defective barrier function and/or bacterial killing. These alterations can lead to a reduced overall microbial diversity with 
loss of beneficial symbionts and/or expansion of pathobionts and ultimately result in an enhanced mucosal adherence and translocation of 
bacteria leading to the development of chronic inflammation involving expansion of T- helper 1 (Th1) and Th17 cells. IEC, intestinal epithelial cells; 
IEL, intraepithelial lymphocyte; DC, dendritic cell; MΦ, macrophage; N, neutrophil; Mo, inflammatory monocyte; ILC, innate lymphoid cell; IgA, 
immunoglobulin A; sIgA, secretory immunoglobulin A; AMPs, anti- microbial peptides
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The microbial communities, inhabiting the distal gut, compete 
for limited availability of diet- derived carbohydrates or host mucus- 
derived glycans.166,167 Hence, diet plays a crucial role in shaping the 
composition of gut microbiota and dietary changes can result in per-
turbation of the gut microbial community structure at species level, 
but the obligate anaerobic Clostridia and Bacteroidia still maintain 
their dominance over facultative anaerobic Enterobacteriaceae in the 
healthy gut.168–171
Under normal conditions, both Clostridia and Bacteroidia use 
glycoside hydrolases to break down complex carbohydrates, bind-
ing proteins to increase carbohydrate concentration at their surface 
and finally an active transport system for transporting carbohydrate 
across the cytoplasmic membrane in Clostridia and across the outer 
membrane in Bacteroidia.166,172 On the other hand, Enterobacteriaceae 
are poorly equipped to degrade complex carbohydrates, due to their 
paucity of glycoside hydrolases. Enterobacteriaceae can only trans-
port passively oligosaccharides through outer membrane diffusion 
channels.172 Hence, Enterobacteriaceae are ill- equipped to compete 
with obligate anaerobes for high- energy nutrients, and this competi-
tive growth disadvantage can explain the dominance of Clostridia and 
Bacteroidia over Enterobacteriaceae in the healthy distal gut.
During inflammation, intestinal epithelial damage, due to an in-
creased shedding of dead epithelial cells, is associated with an en-
hanced availability of epithelial cell membrane- derived phospholipids, 
such as phosphatidylcholine and phosphatidylethanolamine. In partic-
ular, ethanolamine can be used as an exclusive source of carbon and/
or nitrogen by several bacterial species in the Proteobacteria phylum, 
as well as pathogenic bacteria, such as Salmonella and Pseudomonas.173 
The ability to use ethanolamine could contribute to the pathogenesis 
of these bacteria by providing a useful source of carbon and/or nitro-
gen that sustain a successful colonization of the intestine.
An additional mechanism, accounting for the expansion of 
Enterobacteriaceae in the inflamed gut, includes the mucin utilization. 
Mucus layer, coating the intestinal epithelium, is composed by two 
layers; the outer layer is movable, colonized by bacteria and usually 
limits the colonization of commensals, while the inner layer is firmly at-
tached to the epithelium and largely devoid of bacteria.55 The secreted 
gel- forming mucin, MUC2, is a major mucin of the colon mucus in both 
humans and mice. Of note, MUC2- deficient mice showed enhanced 
bacterial adhesion to the surface epithelium, increased intestinal per-
meability and increased susceptibility to develop spontaneous or DSS- 
induced colitis and colorectal cancer.55,174,175
A recent paper underlined the contribution of mucin- derived sialic 
acid, in promoting the expansion of Enterobacteriaceae during intestinal 
inflammation induced in mice by DSS treatment.176 Sialic acid, one of 
the major carbohydrates in mucin, can be taken up by bacteria, which 
are unable to de novo synthesize these sugars, such as E. coli, and then 
incorporated into bacterial capsule and lipooligosaccharides.177
In addition, S. typhimurium and C. difficile, used a common strategy 
of catabolizing microbiota- liberated mucosal sugars, such as fucose 
and sialic acid, during their expansion within the gut.45 Overall, these 
observations suggest that sialic acid catabolism may confer a growth 
advantage to Enterobacteriaceae in the inflamed gut.
Enterobacteriaceae can also overcome other bacteria by producing 
antimicrobial molecules, promoting their blooms in the gut. For exam-
ple, colicins are bacteriocins, produced by some strains of E. coli, are 
lethal for phylogenetically close relatives.178 Of note, production of 
colicin Ib (col1B) conferred a competitive advantage to S. typhimurium 
over sensitive E. coli strains in the inflamed gut.179 Expression of col1B 
is positively regulated by low iron availability and the SOS response, 
conditions that are usually instigated in the inflamed gut by neutro-
phil recruitment and oxidative stress- induced DNA damage, respec-
tively.180–182 Therefore, the inflammatory milieu in the gut seems to 
create an advantageous condition that may potentiate the effects of 
colicins, which act as fitness factors providing a competitive growth 
advantage for Enterobacteriaceae blooms.
Further mechanisms responsible for the expansion of 
Enterobacteriaceae in the inflamed distal gut are host- induced changes 
in the growth conditions in this largely anaerobic environment. During 
inflammation, gut luminal oxygen levels increased due to elevated 
blood flow and hemoglobin. Additionally, new respiratory electron ac-
ceptors generated during intestinal inflammation may support bacte-
rial growth by anaerobic respiration, including nitrate respiration. For 
example, it has been shown that nitrate is generated as a by- product 
of the host inflammatory response. This enrichment in host- derived 
nitrate can confer a fitness advantage for Enterobacteriaceae, such 
as E. coli and S. typhimurium, since genes encoding for nitrate re-
ductase are present in the majority of Enterobacteriaceae, but largely 
absent in obligate anaerobes belonging to Clostridia and Bacteroidia 
classes.148,183,184 In addition, reactive oxygen species (ROS), gener-
ated by inflammatory host response, can react with endogenous sulfur 
compounds (i.e. thiosulfate) to produce a new respiratory electron ac-
ceptor, termed tetrathionate. This newly generated electron acceptor 
provided a selective growth advantage for S. typhimurium over the 
competing fermenting gut microbes in the inflamed gut.185,186 These 
observations indicate that pathogens can utilize host responses to 
outgrow the intestinal microbiota.
Respiratory flexibility of Enterobacteriaceae allows them to respond 
to different oxygen availability within the intestine. For example, in 
the absence of oxygen, E. coli can use nitrate, nitrite, trimethylamine- 
N- oxide (TMAO), dimethyl sulfoxide (DMSO), and fumarate as elec-
tron acceptors,187 while in presence of oxygen E. coli express terminal 
oxidases that use oxygen as electron acceptor.188 The high levels of 
oxygen, derived from elevated blood flow and hemoglobin during 
inflammation, can provide a growth advantage for facultative anaer-
obes, such as Enterobacteriaceae, over the obligate anaerobes, such 
as Clostridia and Bacteroidia. For instance, streptomycin treatment led 
to depletion of butyrate- producing commensal Clostridia in mice, re-
sulting in reduced butyrate levels, elevated epithelial oxygenation, and 
aerobic bloom of S. typhimurium.34 In addition, C. rodentium used a 
type III secretion system (T3SS) to promote colonic crypt hyperplasia 
in mice, which in turn increased oxygenation of the surface epithelium 
and fueled an aerobic expansion of C. rodentium in the colon.189
A further mechanism that accounts for Enterobacteriaceae blooms 
in the intestinal inflammation is the metal acquisition. Iron is a vital 
nutrient for both the host and the pathogenic bacteria, and it is mostly 
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sequestered in intracellular storages, hence inaccessible to patho-
gens.190 However, to bypass this iron withholding, many pathogens 
have evolved high- affinity iron uptake mechanisms that compete 
against host- mediated restriction. These uptake systems include re-
lease of iron- chelating siderophores, heme acquisition systems, and 
transferrin/lactoferrin receptors.190 For example, E. coli was able to 
produce enterobactin, a catecholate siderophore that acted as a potent 
inhibitor of neutrophil bacteriocidal myeloperoxidase and conferred a 
distinct survival advantage to E. coli in the inflamed gut.191 Based on 
these observations, it is conceivable that siderophores, released from 
E. coli, serve as dual- purpose molecules, both in iron acquisition and in 
protection from host- derived oxidative stress.
Analysis of the genomes of phylogenetically diverse AIEC strains, 
isolated from patients with CD, dogs with granulomatous colitis and 
mice with ileitis, revealed that AIEC strains overexpressed genes 
encoding iron acquisition, such as chu operon, as compared to non- 
pathogenic E. coli. Additionally, AIEC required iron for growing and 
the presence of chuA (heme iron acquisition) correlated with their 
ability to persist within macrophages.192 These results were further 
supported by the observation that siderophore aerobactin enhanced 
intracellular survival in macrophages and colonization of the mouse 
intestine by AIEC NRG857c (O83:H1), a clinical isolate of AIEC from 
the ileum of a CD patient.193
Overall, these studies highlight the pivotal role of iron acquisi-
tion in boosting the expansion of more virulent Enterobacteriaceae 
in the inflamed gut. Enterobacteriaceae also have evolved strate-
gies to acquire other metals, such as zinc and manganese, to ben-
efit their own growth in the inflamed gut.194–196 Inflammation in 
the gut commonly fosters the emergence of more virulent species 
of Enterobacteriaceae that have evolved multiple strategies to evade 
host immune  responses, to outcompete commensal bacteria and to 
thrive in the inflamed gut.
7  | THE MICROBIAL BASIS OF 
INFLAMMATORY BOWEL DISEASES
7.1 | Involvement of microbiota in the pathogenesis 
of inflammatory bowel diseases
A microbial basis for the development of IBD has long been sus-
pected, but causative bacteria have not been identified. Several ex-
perimental and clinical studies have shown that the gut microbiota 
is an essential factor in driving inflammation in IBD. In humans, the 
first demonstration of the involvement of intestinal microbiota in 
the pathogenesis of IBD came from clinical studies in patients with 
CD, showing that fecal stream diversion prevented recurrence of 
ileal CD 197 and that exposure of the terminal ileum to the intestinal 
content triggered postoperative recurrence in patients with CD.198 
Furthermore, treatment with antibiotics, such as metronidazole, 
ciprofloxacin or rifaximin, has been associated with clinical improve-
ment in patients with IBD,199,200 even though the use of antibiotics 
as primary or adjuvant therapy for inducing remission in patients with 
IBD is still controversial.
Animal models of IBD also suggested a role for gut microbiota in 
the pathogenesis of these diseases. For instance, SPF mice carrying 
null mutations in T- cell antigen receptor (TCR) genes developed colitis 
but the germ- free animals were disease- free. Furthermore, intestinal 
inflammation was not observed in germ- free TCR- deficient mice col-
onized with a defined commensal community.201 These observations 
strongly suggest that intestinal inflammation might be initiated by spe-
cific microbes normally present in the gut flora that have yet to be 
identified.
In addition, HLA- B27- transgenic rats, interleukin (IL)- 10- and IL- 
2- deficient mice raised under conventional conditions spontaneously 
developed chronic colitis, but the germ- free condition prevented the 
development of intestinal pathology.202–204
Additional evidence, arguing for a pathogenic role of the gut mi-
crobiota in IBD, derived from an UC- like colitis model that sponta-
neously occurred in TRUC mice and that was cured by broad- spectrum 
antibiotics.205 The role of microbiota in driving intestinal inflammation 
has also been confirmed in a model of chronic CD- like ileitis sponta-
neously developed in SPF, but not germ- free, mice carrying a dele-
tion in the tumor necrosis factor AU- rich elements.206 Taken together, 
these observations suggest that the luminal microbes provide the 
stimulus for host immune responses that ultimately lead to mucosal 
damage in genetically susceptible hosts.
The intestinal epithelial cells and immune cells are constantly in 
contact with foreign material, including dietary and microbial factors. 
The mucosal immune system is usually able to protect the host by 
mounting inflammatory responses against pathogens, but it has also 
evolved tolerance mechanisms toward not pathogenic bacteria and 
diet- derived factors.
In IBD, inflammation might arise from abnormal host- microbial 
interactions that lead to the perturbation of intestinal homeostasis. 
Notably, patients with IBD showed abnormal mucosal secretion of IgG 
antibodies, as opposed to a physiological IgA response, against gut 
commensals 126 as well as higher serum reactivity toward microbial 
antigens 207 indicating that the tolerance mechanisms toward com-
mensals may be abrogated in patients with IBD.
In addition, T cells isolated from inflamed mucosa of CD patients 
were hyper- responsive to the stimulation with antigens derived from 
gut commensals.208 Similarly, intestinal cells isolated from inflamed 
areas of IBD patients were activated by the exposure to sonicated 
samples of both autologous and heterologous gut microbiota, while 
mucosal cells isolated from normal individuals reacted only toward 
antigens derived from heterologous intestinal microflora,209 suggest-
ing that the immune tolerance to self- intestinal flora is lost in patients 
with IBD.
It is also conceivable that hyper- reactive T cells can be induced by 
specific microorganisms. For instance, flagellin is a commensal bacte-
rial protein, known to be a dominant antigen in CD. Flagellin was able 
to trigger an innate immune response via Toll- like receptor 5 and adop-
tive transfer of flagellin- specific CD4+ T cells into SCID mice induced 
severe colitis.210
IL- 17- producing T- helper (Th17) cells are potent mediators of in-
flammation in different organs, including the intestine.211 Colonization 
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of the small intestine of mice with a single commensal, such as SFB, 
induced the appearance of Th17 cells in the intestinal lamina propria 
and consistently antibiotic treatment inhibited differentiation of Th17 
cells.88 Although SFB contributes to shaping the intestinal immune 
system and their presence has been reported in humans,212 their role 
in IBD is still unclear and requires further studies. Alike SFB that typ-
ically adhere tightly to intestinal epithelium without invading the epi-
thelial cells, other mucus inhabitants, such as Akkermansia species and 
Mucispirillum genus, have been reported to accumulate in the intestine 
of mice experiencing DSS- induced recurring colitis.213 Thus, it is con-
ceivable that mucus- dwelling commensals, due to their proximity to 
the intestinal epithelium, can trigger abnormal host immune responses 
leading to chronic inflammation and ultimately to mucosal damage in 
IBD (Figure 3).
The crucial role of intestinal microbes in the pathogenesis of IBD 
has been further strengthened by the identification of several IBD- 
susceptibility genes, many involved in mediating host responses to 
gut microbes. The first identified gene, strongly associated with the 
risk of developing CD, was the nucleotide- binding oligomerization 
domain- containing protein 2 (NOD2) encoding for an intracellular re-
ceptor for peptidoglycan- derived muramyl dipeptide (MDP).214,215 The 
mechanisms by which NOD2 variants contribute to CD pathogenesis 
are still unclear, but several hypotheses have been proposed including 
an impaired MDP sensing in antigen- presenting cells, defective anti-
microbial responses in Paneth cells or an altered intraepithelial auto-
phagy.216 However, whether CD- related inflammation is triggered by 
defective antimicrobial activity within the intestinal crypts and exces-
sive accumulation of pathogenic bacteria and/or pathobionts is still 
controversial and requires further studies.
Additional IBD- susceptibility genes, such as autophagy- related 
protein 16- like 1 (ATG16L1) and immunity- related GTPase family M 
(IRGM), are involved in the innate defense mechanism of autoph-
agy.217,218 Since functional autophagy is required to limit the replica-
tion of intracellular CD- associated AIEC,219,220 it is conceivable that 
polymorphisms in these genes could affect the autophagy pathway 
and promote intracellular proliferation of invasive pathogens leading 
to chronic inflammation in IBD.
Interestingly, a recent paper has proposed a new gene- 
environmental etiology for IBD, revealing that polymorphisms in 
CD- associated genes, NOD2 and ATG16L1, were associated with a 
defective sensing of protective signals derived from the microbiota.221
Taken together, the identification of the IBD- susceptibility genes 
has shed light on essential relationships between genes and gut mi-
crobiota, particularly on host immune functions that can affect the 
assembly of intestinal microbiota.
7.2 | Dysbiosis in inflammatory bowel diseases
Advances in culture- independent technologies have provided a more 
detailed characterization of the gut microbiota in patients with IBD. 
Analysis of mucosa- associated and luminal bacteria revealed the 
presence of a dysbiotic microbiota, marked by a reduced overall mi-
crobial diversity. Multiple studies have shown less complex profiles 
of commensal bacteria in IBD patients that seem to be associated 
with a temporal instability of dominant species when compared to 
healthy individuals.145,222–224 An important observation that derived 
from this evidence is that a loss of total bacterial diversity could 
have detrimental effects on host health. It has now become evi-
dent that distinct members of the gut microbiota exert diverse and 
non- redundant effects on the host immune system,225 suggesting 
that a more complex collection of organisms is required for maximal 
benefits to the host. Given that, depletion of members of the phyla 
Firmicutes and Bacteroidetes, described in patients with IBD,145 might 
contribute to the intestinal inflammation seen in these patients. Of 
note, Bacteriodes fragilis has been shown to protect from the devel-
opment of experimental IBD in mice through the immunomodulatory 
activity of its capsular polysaccharide A (PSA).226 Specific changes, 
among the phylum of Firmicutes, observed in patients with ileal CD 
included disappearance of Faecalibacterium prausnitzii, a commensal 
microbial species that was able to secrete anti- inflammatory metabo-
lites. Interestingly, a lower proportion of F. prausnitzii in ileal mucosa 
was associated with an enhanced risk of postoperative recurrence 
of ileal CD.227 In addition, reduced levels of microbes that produce 
short- chain fatty acids (SCFA) have been observed in patients with 
IBD. The downside of this loss is further strengthened by the evi-
dence that SCFA- producing bacteria can provide protection from 
experimental colitis through the differentiation and expansion of 
regulatory T cells.228
The loss of beneficial microbes and their immunomodulatory 
molecules can also provide the opportunity for the expansion of 
pathogens and/or pathobionts. For instance, a higher number of 
mucosa- associated Enterobacteriaceae with invasive properties or the 
presence of intramucosal E. coli has been described in patients with 
CD.139,140
However, there are still questions that remain unanswered. For 
instance, it is still unclear if intestinal dysbiosis, observed in patients 
with IBD, is a cause or consequence of gut inflammation. Another 
key question that remains is whether these diseases are caused by 
the expansion of pathobionts and/or loss of beneficial symbionts or 
simply secondary to an aberrant host immune response against gut 
symbionts.
Two recent cohort studies in pediatric treatment- naive IBD pa-
tients have provided the opportunity to analyze the gut microbiota 
in patients at the very earliest stage of disease and prior to treatment 
intervention, showing that intestinal dysbiosis correlated strongly with 
disease status.229,230
Therefore, we can speculate that intestinal inflammation might 
be initiated by a specific symbiotic bacterium, or group of symbionts 
normally present at low abundance in the intestine, that may bloom 
under advantageous conditions, such as mutations in anti- microbial 
genes. As a result, exaggerated host immune responses may ulti-
mately lead to chronic inflammation that definitively disrupts the 
intestinal homeostasis in favor of a more extreme dysbiosis. Hence, 
unraveling the specific microbial contribution to the development 
of IBD will improve the understanding and management of these 
diseases.
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8  | CONCLUDING REMARKS
The integral roles of the gut microbiota in resisting colonization of en-
teric pathogens, educating and promoting the maturation of the host 
immune system, and host metabolism, as shown by numerous studies 
in the past few years, underscore the need to understand mechanisms 
underlying the myriad of supportive roles of the gut microbiota in 
human health. Our recent studies on systemic production of comple-
ment C3 and hemopexin initiated by intestinally induced IL- 22, as well 
as gut microbiota- induced systemic IgG antibodies that can potentially 
target pathogens with shared antigens, have unraveled a previously 
less understood role of the gut microbiota in combating systemic in-
fection. This knowledge can be potentially harnessed in developing 
treatment for systemic infection that may lead to fatal sepsis. There 
are likely many others functions of the gut microbiota in equipping 
the host for systemic infection that are yet to be discovered. There 
has been increasing evidence linking gut dysbiosis with the manifes-
tation of diseases involving chronic gut inflammation, most notably 
inflammatory bowel disease. Dampening gut inflammation, utilizing 
resistant competitors (probiotics), or maneuvering nutritional changes 
(such as prebiotics and metals) might be potential approaches to re-
stricting blooms of Enterobacterieaceae or disease- causing bacteria in 
the future.
ACKNOWLEDGEMENTS
This work was supported by NIH grants T32HL007517 and 
5P30DK034933 (to M. Y. Z.), T32DK094775 (to J. M. P), and 
DK091191 and DK095782 (to G. N.).
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.
REFERENCES
 1. Marcobal A, Barboza M, Froehlich JW, et al. Consumption of human 
milk oligosaccharides by gut- related microbes. J Agric Food Chem. 
2010;58:5334-5340.
 2. Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut micro-
biota in immunity and inflammatory disease. Nat Rev Immunol. 
2013;13:321-335.
 3. Freter R. The fatal enteric cholera infection in the guinea pig, 
achieved by inhibition of normal enteric flora. J Infect Dis. 1955;97: 
57-65.
 4. Bohnhoff M, Drake BL, Miller CP. Effect of streptomycin on suscep-
tibility of intestinal tract to experimental Salmonella infection. Proc 
Soc Exp Biol Med. 1954;86:132-137.
 5. Pultz NJ, Stiefel U, Subramanyan S, Helfand MS, Donskey CJ. 
Mechanisms by which anaerobic microbiota inhibit the establish-
ment in mice of intestinal colonization by vancomycin- resistant 
Enterococcus. J Infect Dis. 2005;191:949-956.
 6. Hammami R, Fernandez B, Lacroix C, Fliss I. Anti- infective properties 
of bacteriocins: an update. Cell Mol Life Sci. 2013;70:2947-2967.
 7. Gillor O, Giladi I, Riley MA. Persistence of colicinogenic Escherichia 
coli in the mouse gastrointestinal tract. BMC Microbiol. 2009;9:165.
 8. Kommineni S, Bretl DJ, Lam V, et al. Bacteriocin production aug-
ments niche competition by enterococci in the mammalian gastroin-
testinal tract. Nature. 2015;526:719-722.
 9. Corr SC, Li Y, Riedel CU, O’Toole PW, Hill C, Gahan CG. Bacteriocin pro-
duction as a mechanism for the antiinfective activity of Lactobacillus 
salivarius UCC118. Proc Natl Acad Sci USA. 2007;104:7617-7621.
 10. Sassone-Corsi M, Nuccio SP, Liu H, et al. Microcins mediate com-
petition among Enterobacteriaceae in the inflamed gut. Nature. 
2016;540:280-283.
 11. Kirkup BC, Riley MA. Antibiotic- mediated antagonism leads to a bac-
terial game of rock- paper- scissors in vivo. Nature. 2004;428:412-414.
 12. Manrique P, Bolduc B, Walk ST, van der Oost J, de Vos WM, 
Young MJ. Healthy human gut phageome. Proc Natl Acad Sci USA. 
2016;113:10400-10405.
 13. Minot S, Sinha R, Chen J, et al. The human gut virome: Inter- 
individual variation and dynamic response to diet. Genome Res. 
2011;21:1616-1625.
 14. Breitbart M, Hewson I, Felts B, et al. Metagenomic analyses of 
an uncultured viral community from human feces. J Bacteriol. 
2003;185:6220-6223.
 15. Stern A, Mick E, Tirosh I, Sagy O, Sorek R. CRISPR targeting reveals a 
reservoir of common phages associated with the human gut microbi-
ome. Genome Res. 2012;22:1985-1994.
 16. Reyes A, Haynes M, Hanson N, et al. Viruses in the faecal microbiota 
of monozygotic twins and their mothers. Nature. 2010;466:334-338.
 17. Diard M, Bakkeren E, Cornuault JK, et al. Inflammation boosts 
bacteriophage transfer between Salmonella spp. Science. 
2017;355:1211-1215.
 18. Duerkop BA, Clements CV, Rollins D, Rodrigues JL, Hooper LV. A 
composite bacteriophage alters colonization by an intestinal com-
mensal bacterium. Proc Natl Acad Sci USA. 2012;109:17621-17626.
 19. Weinbauer MG. Ecology of prokaryotic viruses. FEMS Microbiol Rev. 
2004;28:127-181.
 20. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. 
Antimicrob Agents Chemother. 2001;45:649-659.
 21. Schwarz S, Hood RD, Mougous JD. What is type VI secretion doing 
in all those bugs? Trends Microbiol. 2010;18:531-537.
 22. Russell AB, Wexler AG, Harding BN, et al. A type VI secretion- related 
pathway in Bacteroidetes mediates interbacterial antagonism. Cell 
Host Microbe. 2014;16:227-236.
 23. Wexler AG, Bao Y, Whitney JC, et al. Human symbionts inject and 
neutralize antibacterial toxins to persist in the gut. Proc Natl Acad Sci 
USA. 2016;113:3639-3644.
 24. Hecht AL, Casterline BW, Earley ZM, Goo YA, Goodlett DR, Bubeck 
Wardenburg J. Strain competition restricts colonization of an enteric 
pathogen and prevents colitis. EMBO Rep. 2016;17:1281-1291.
 25. Bohnhoff M, Miller CP, Martin WR. Resistance of the mouse’s intes-
tinal tract to experimental salmonella infection. I. Factors which in-
terfere with the initiation of infection by oral inoculation. J Exp Med. 
1964;120:805-816.
 26. Cherrington CA, Hinton M, Pearson GR, Chopra I. Short- chain organic 
acids at ph 5.0 kill Escherichia coli and Salmonella spp. without caus-
ing membrane perturbation. The. J Appl Bacteriol. 1991;70:161-165.
 27. Shin R, Suzuki M, Morishita Y. Influence of intestinal anaerobes and 
organic acids on the growth of enterohaemorrhagic Escherichia coli 
O157:H7. J Med Microbiol. 2002;51:201-206.
 28. Rolfe RD. Role of volatile fatty acids in colonization resistance to 
Clostridium difficile. Infect Immun. 1984;45:185-191.
 29. Kim YG, Sakamoto K, Seo SU, et al. Neonatal acquisition of Clostridia 
species protects against colonization by bacterial pathogens. Science. 
2017;356:315-319.
 30. Bohnhoff M, Miller CP, Martin WR. Resistance of the mouse’s in-
testinal tract to experimental salmonella infection. II. Factors re-
sponsible for its loss following streptomycin treatment. J Exp Med. 
1964;120:817-828.
     |  85PICKARD et Al.
 31. Huang Y, Suyemoto M, Garner CD, Cicconi KM, Altier C. Formate 
acts as a diffusible signal to induce Salmonella invasion. J Bacteriol. 
2008;190:4233-4241.
 32. Gantois I, Ducatelle R, Pasmans F, et al. Butyrate specifically down- 
regulates salmonella pathogenicity island 1 gene expression. Appl 
Environ Microbiol. 2006;72:946-949.
 33. Lawhon SD, Maurer R, Suyemoto M, Altier C. Intestinal short- 
chain fatty acids alter Salmonella typhimurium invasion gene 
expression and virulence through BarA/SirA. Mol Microbiol. 
2002;46:1451-1464.
 34. Rivera-Chavez F, Zhang LF, Faber F, et al. Depletion of butyrate- 
producing clostridia from the gut microbiota drives an aerobic lumi-
nal expansion of Salmonella. Cell Host Microbe. 2016;19:443-454.
 35. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by 
human intestinal bacteria. J Lipid Res. 2006;47:241-259.
 36. Buffie CG, Bucci V, Stein RR, et al. Precision microbiome reconsti-
tution restores bile acid mediated resistance to Clostridium difficile. 
Nature. 2015;517:205-208.
 37. Theriot CM, Koenigsknecht MJ, Carlson PE Jr, et al. Antibiotic- 
induced shifts in the mouse gut microbiome and metabolome in-
crease susceptibility to Clostridium difficile infection. Nat Commun. 
2014;5:3114.
 38. Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial de-
fense in the small intestine by the nuclear bile acid receptor. Proc 
Natl Acad Sci USA. 2006;103:3920-3925.
 39. Freter R, Brickner H, Botney M, Cleven D, Aranki A. Mechanisms that 
control bacterial populations in continuous- flow culture models of 
mouse large intestinal flora. Infect Immun. 1983;39:676-685.
 40. Wilson KH, Perini F. Role of competition for nutrients in suppres-
sion of Clostridium difficile by the colonic microflora. Infect Immun. 
1988;56:2610-2614.
 41. Guiot HF. Role of competition for substrate in bacterial antagonism 
in the gut. Infect Immun. 1982;38:887-892.
 42. Sweeney NJ, Klemm P, McCormick BA, et al. The Escherichia coli 
K- 12 gntP gene allows E. coli F- 18 to occupy a distinct nutritional 
niche in the streptomycin- treated mouse large intestine. Infect 
Immun. 1996;64:3497-3503.
 43. Lee SM, Donaldson GP, Mikulski Z, Boyajian S, Ley K, Mazmanian SK. 
Bacterial colonization factors control specificity and stability of the 
gut microbiota. Nature. 2013;501:426-429.
 44. Maldonado-Gomez MX, Martinez I, Bottacini F, et al. Stable engraft-
ment of Bifidobacterium longum AH1206 in the human gut depends 
on individualized features of the resident microbiome. Cell Host 
Microbe. 2016;20:515-526.
 45. Ng KM, Ferreyra JA, Higginbottom SK, et al. Microbiota- liberated 
host sugars facilitate post- antibiotic expansion of enteric pathogens. 
Nature. 2013;502:96-99.
 46. Ferreyra JA, Wu KJ, Hryckowian AJ, Bouley DM, Weimer BC, 
Sonnenburg JL. Gut microbiota- produced succinate promotes C. dif-
ficile infection after antibiotic treatment or motility disturbance. Cell 
Host Microbe. 2014;16:770-777.
 47. Kamada N, Kim YG, Sham HP, et al. Regulated virulence controls the 
ability of a pathogen to compete with the gut microbiota. Science. 
2012;336:1325-1329.
 48. Kamada N, Sakamoto K, Seo SU, et al. Humoral immunity in the 
gut selectively targets phenotypically virulent attaching- and- 
effacing bacteria for intraluminal elimination. Cell Host Microbe. 
2015;17:617-627.
 49. McNulty NP, Wu M, Erickson AR, et al. Effects of diet on resource 
utilization by a model human gut microbiota containing Bacteroides 
cellulosilyticus WH2, a symbiont with an extensive glycobiome. PLoS 
Biol. 2013;11:e1001637.
 50. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The 
effect of diet on the human gut microbiome: A metagenomic analysis 
in humanized gnotobiotic mice. Sci Transl Med. 2009;1:6ra14.
 51. Desai MS, Seekatz AM, Koropatkin NM, et al. A dietary fiber- 
deprived gut microbiota degrades the colonic mucus barrier and en-
hances pathogen susceptibility. Cell. 2016;167(1339–1353):e1321.
 52. Deriu E, Liu JZ, Pezeshki M, et al. Probiotic bacteria reduce salmo-
nella typhimurium intestinal colonization by competing for iron. Cell 
Host Microbe. 2013;14:26-37.
 53. Jin LZ, Marquardt RR, Zhao X. A strain of Enterococcus faecium 
(18C23) inhibits adhesion of enterotoxigenic Escherichia coli K88 
to porcine small intestine mucus. Appl Environ Microbiol. 2000;66: 
4200-4204.
 54. Johansson ME, Jakobsson HE, Holmen-Larsson J, et al. Normalization 
of host intestinal mucus layers requires long- term microbial coloni-
zation. Cell Host Microbe. 2015;18:582-592.
 55. Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, 
Hansson GC. The inner of the two Muc2 mucin- dependent mucus 
layers in colon is devoid of bacteria. Proc Natl Acad Sci USA. 
2008;105:15064-15069.
 56. Bergstrom JH, Birchenough GM, Katona G, et al. Gram- positive bac-
teria are held at a distance in the colon mucus by the lectin- like pro-
tein ZG16. Proc Natl Acad Sci USA. 2016;113:13833-13838.
 57. Vaishnava S, Yamamoto M, Severson KM, et al. The antibacterial lec-
tin RegIIIgamma promotes the spatial segregation of microbiota and 
host in the intestine. Science. 2011;334:255-258.
 58. Bergstrom KS, Kissoon-Singh V, Gibson DL, et al. Muc2 pro-
tects against lethal infectious colitis by disassociating pathogenic 
and commensal bacteria from the colonic mucosa. PLoS Pathog. 
2010;6:e1000902.
 59. Zarepour M, Bhullar K, Montero M, et al. The mucin Muc2 lim-
its pathogen burdens and epithelial barrier dysfunction during 
Salmonella enterica serovar Typhimurium colitis. Infect Immun. 
2013;81:3672-3683.
 60. Arike L, Holmen-Larsson J, Hansson GC. Intestinal Muc2 mucin O- 
glycosylation is affected by microbiota and regulated by differential 
expression of glycosyltranferases. Glycobiology. 2017;27:318-328.
 61. Umesaki Y, Tohyama K, Mutai M. Appearance of fucolipid after con-
ventionalization of germ- free mice. J Biochem. 1981;90:559-561.
 62. Hooper LV, Xu J, Falk PG, Midtvedt T, Gordon JI. A molecular sen-
sor that allows a gut commensal to control its nutrient founda-
tion in a competitive ecosystem. Proc Natl Acad Sci USA. 1999;96: 
9833-9838.
 63. Pickard JM, Maurice CF, Kinnebrew MA, et al. Rapid fucosylation of 
intestinal epithelium sustains host- commensal symbiosis in sickness. 
Nature. 2014;514:638-641.
 64. Goto Y, Obata T, Kunisawa J, et al. Innate lymphoid cells regulate 
intestinal epithelial cell glycosylation. Science. 2014;345:1254009.
 65. Pacheco AR, Curtis MM, Ritchie JM, et al. Fucose sensing regulates 
bacterial intestinal colonization. Nature. 2012;492:113-117.
 66. Pham TA, Clare S, Goulding D, et al. Epithelial IL- 22RA1- mediated 
fucosylation promotes intestinal colonization resistance to an oppor-
tunistic pathogen. Cell Host Microbe. 2014;16:504-516.
 67. Faber F, Tran L, Byndloss MX, et al. Host- mediated sugar oxi-
dation promotes post- antibiotic pathogen expansion. Nature. 
2016;534:697-699.
 68. Josefsdottir KS, Baldridge MT, Kadmon CS, King KY. Antibiotics im-
pair murine hematopoiesis by depleting the intestinal microbiota. 
Blood. 2017;129:729-739.
 69. Khosravi A, Yanez A, Price JG, et al. Gut microbiota promote he-
matopoiesis to control bacterial infection. Cell Host Microbe. 
2014;15:374-381.
 70. Fiedler K, Kokai E, Bresch S, Brunner C. MyD88 is involved in my-
eloid as well as lymphoid hematopoiesis independent of the pres-
ence of a pathogen. Am J Blood Res. 2013;3:124-140.
 71. Balmer ML, Schurch CM, Saito Y, et al. Microbiota- derived com-
pounds drive steady- state granulopoiesis via MyD88/TICAM signal-
ing. J Immunol. 2014;193:5273-5283.
86  |     PICKARD et Al.
 72. Deshmukh HS, Liu Y, Menkiti OR, et al. The microbiota regulates 
neutrophil homeostasis and host resistance to Escherichia coli K1 
sepsis in neonatal mice. Nat Med. 2014;20:524-530.
 73. Zhang D, Chen G, Manwani D, et al. Neutrophil ageing is regulated 
by the microbiome. Nature. 2015;525:528-532.
 74. Burberry A, Zeng MY, Ding L, et al. Infection mobilizes hematopoi-
etic stem cells through cooperative NOD- like receptor and Toll- like 
receptor signaling. Cell Host Microbe. 2014;15:779-791.
 75. Carlens J, Wahl B, Ballmaier M, Bulfone-Paus S, Forster R, Pabst 
O. Common gamma- chain- dependent signals confer selective 
survival of eosinophils in the murine small intestine. J Immunol. 
2009;183:5600-5607.
 76. Sugawara R, Lee EJ, Jang MS, et al. Small intestinal eosinophils reg-
ulate Th17 cells by producing IL- 1 receptor antagonist. J Exp Med. 
2016;213:555-567.
 77. Yang BG, Seoh JY, Jang MH. Regulatory eosinophils in inflammation 
and metabolic disorders. Immune Netw. 2017;17:41-47.
 78. Davies LC, Taylor PR. Tissue- resident macrophages: Then and now. 
Immunology. 2015;144:541-548.
 79. Bain CC, Bravo-Blas A, Scott CL, et al. Constant replenishment from 
circulating monocytes maintains the macrophage pool in the intes-
tine of adult mice. Nat Immunol. 2014;15:929-937.
 80. Lotz M, Gutle D, Walther S, Menard S, Bogdan C, Hornef MW. 
Postnatal acquisition of endotoxin tolerance in intestinal epithelial 
cells. J Exp Med. 2006;203:973-984.
 81. Smythies LE, Sellers M, Clements RH, et al. Human intestinal mac-
rophages display profound inflammatory anergy despite avid phago-
cytic and bacteriocidal activity. J Clin Invest. 2005;115:66-75.
 82. Franchi L, Kamada N, Nakamura Y, et al. NLRC4- driven produc-
tion of IL- 1beta discriminates between pathogenic and commen-
sal bacteria and promotes host intestinal defense. Nat Immunol. 
2012;13:449-456.
 83. Shaw MH, Kamada N, Kim YG, Nunez G. Microbiota- induced IL- 
1beta, but not IL- 6, is critical for the development of steady- state 
TH17 cells in the intestine. J Exp Med. 2012;209:251-258.
 84. Seo SU, Kamada N, Munoz-Planillo R, et al. Distinct commensals 
induce interleukin- 1beta via NLRP3 inflammasome in inflammatory 
monocytes to promote intestinal inflammation in response to injury. 
Immunity. 2015;42:744-755.
 85. Hirota K, Ahlfors H, Duarte JH, Stockinger B. Regulation and func-
tion of innate and adaptive interleukin- 17- producing cells. EMBO 
Rep. 2012;13:113-120.
 86. Ivanov II, Frutos Rde L, Manel N, et al. Specific microbiota direct the 
differentiation of IL- 17- producing T- helper cells in the mucosa of the 
small intestine. Cell Host Microbe. 2008;4:337-349.
 87. Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, et al. The key role of 
segmented filamentous bacteria in the coordinated maturation of 
gut helper T cell responses. Immunity. 2009;31:677-689.
 88. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells 
by segmented filamentous bacteria. Cell. 2009;139:485-498.
 89. Geuking MB, Cahenzli J, Lawson MA, et al. Intestinal bacterial col-
onization induces mutualistic regulatory T cell responses. Immunity. 
2011;34:794-806.
 90. Sano T, Huang W, Hall JA, et al. An IL- 23R/IL- 22 circuit regulates ep-
ithelial serum amyloid A to promote local effector Th17 responses. 
Cell. 2015;163:381-393.
 91. Atarashi K, Tanoue T, Ando M, et al. Th17 cell induction by ad-
hesion of microbes to intestinal epithelial cells. Cell. 2015;163: 
367-380.
 92. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota mod-
ulates the anticancer immune effects of cyclophosphamide. Science. 
2013;342:971-976.
 93. Smith PM, Howitt MR, Panikov N, et al. The microbial metabo-
lites, short- chain fatty acids, regulate colonic Treg cell homeostasis. 
Science. 2013;341:569-573.
 94. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T- cell devel-
opment by a commensal bacterium of the intestinal microbiota. Proc 
Natl Acad Sci USA. 2010;107:12204-12209.
 95. Round JL, Lee SM, Li J, et al. The Toll- like receptor 2 pathway es-
tablishes colonization by a commensal of the human microbiota. 
Science. 2011;332:974-977.
 96. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe- derived 
butyrate induces the differentiation of colonic regulatory T cells. 
Nature. 2013;504:446-450.
 97. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by com-
mensal bacteria promote peripheral regulatory T- cell generation. 
Nature. 2013;504:451-455.
 98. Sonnenberg GF, Artis D. Innate lymphoid cell interactions with mi-
crobiota: Implications for intestinal health and disease. Immunity. 
2012;37:601-610.
 99. Kiss EA, Vonarbourg C, Kopfmann S, et al. Natural aryl hydrocarbon 
receptor ligands control organogenesis of intestinal lymphoid folli-
cles. Science. 2011;334:1561-1565.
 100. Lee JS, Cella M, McDonald KG, et al. AHR drives the develop-
ment of gut ILC22 cells and postnatal lymphoid tissues via path-
ways dependent on and independent of Notch. Nat Immunol. 
2011;13:144-151.
 101. Qiu J, Heller JJ, Guo X, et al. The aryl hydrocarbon receptor regulates 
gut immunity through modulation of innate lymphoid cells. Immunity. 
2012;36:92-104.
 102. Crellin NK, Trifari S, Kaplan CD, Satoh-Takayama N, Di Santo JP, 
Spits H. Regulation of cytokine secretion in human CD127(+) 
LTi- like innate lymphoid cells by Toll- like receptor 2. Immunity. 
2010;33:752-764.
 103. Hughes T, Becknell B, Freud AG, et al. Interleukin- 1beta selectively 
expands and sustains interleukin- 22+ immature human natural killer 
cells in secondary lymphoid tissue. Immunity. 2010;32:803-814.
 104. Cording S, Medvedovic J, Cherrier M, Eberl G. Development and 
regulation of RORgammat(+) innate lymphoid cells. FEBS Lett. 
2014;588:4176-4181.
 105. Tsuji M, Suzuki K, Kitamura H, et al. Requirement for lymphoid tissue- 
inducer cells in isolated follicle formation and T cell- independent im-
munoglobulin A generation in the gut. Immunity. 2008;29:261-271.
 106. Sonnenberg GF, Monticelli LA, Alenghat T, et al. Innate lymphoid 
cells promote anatomical containment of lymphoid- resident com-
mensal bacteria. Science. 2012;336:1321-1325.
 107. Abt MC, Lewis BB, Caballero S, et al. Innate immune defenses me-
diated by two ILC subsets are critical for protection against acute 
Clostridium difficile infection. Cell Host Microbe. 2015;18:27-37.
 108. Hasegawa M, Yada S, Liu MZ, et al. Interleukin- 22 regulates 
the complement system to promote resistance against patho-
bionts after pathogen- induced intestinal damage. Immunity. 
2014;41:620-632.
 109. Sakamoto K, Kim YG, Hara H, et al. IL- 22 controls iron- dependent 
nutritional immunity against systemic bacterial infections. Sci 
Immunol. 2017;2:eaai8371.
 110. Hepworth MR, Fung TC, Masur SH, et al. Immune tolerance. Group 
3 innate lymphoid cells mediate intestinal selection of commensal 
bacteria- specific CD4(+) T cells. Science. 2015;348:1031-1035.
 111. Brandtzaeg P, Halstensen TS, Kett K, et al. Immunobiology and 
 immunopathology of human gut mucosa: Humoral immunity 
and intraepithelial lymphocytes. Gastroenterology. 1989;97: 
1562-1584.
 112. Wesemann DR, Portuguese AJ, Meyers RM, et al. Microbial colo-
nization influences early B- lineage development in the gut lamina 
propria. Nature. 2013;501:112-115.
 113. Talham GL, Jiang HQ, Bos NA, Cebra JJ. Segmented filamentous 
bacteria are potent stimuli of a physiologically normal state of 
the murine gut mucosal immune system. Infect Immun. 1999;67: 
1992-2000.
     |  87PICKARD et Al.
 114. Hirota K, Turner JE, Villa M, et al. Plasticity of Th17 cells in Peyer’s 
patches is responsible for the induction of T cell- dependent IgA re-
sponses. Nat Immunol. 2013;14:372-379.
 115. Yel L. Selective IgA deficiency. J Clin Immunol. 2010;30:10-16.
 116. Macpherson AJ, Geuking MB, McCoy KD. Homeland secu-
rity: IgA immunity at the frontiers of the body. Trends Immunol. 
2012;33:160-167.
 117. Johansen FE, Pekna M, Norderhaug IN, et al. Absence of epithelial 
immunoglobulin A transport, with increased mucosal leakiness, in 
polymeric immunoglobulin receptor/secretory component- deficient 
mice. J Exp Med. 1999;190:915-922.
 118. Shimada S, Kawaguchi-Miyashita M, Kushiro A, et al. Generation of 
polymeric immunoglobulin receptor- deficient mouse with marked 
reduction of secretory IgA. J Immunol. 1999;163:5367-5373.
 119. Palm NW, de Zoete MR, Cullen TW, et al. Immunoglobulin A coating 
identifies colitogenic bacteria in inflammatory bowel disease. Cell. 
2014;158:1000-1010.
 120. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev 
Immunol. 2008;8:205-217.
 121. Herbst T, Sichelstiel A, Schar C, et al. Dysregulation of allergic airway 
inflammation in the absence of microbial colonization. Am J Respir 
Crit Care Med. 2011;184:198-205.
 122. Forsythe P, Inman MD, Bienenstock J. Oral treatment with live 
Lactobacillus reuteri inhibits the allergic airway response in mice. Am 
J Respir Crit Care Med. 2007;175:561-569.
 123. Russell SL, Gold MJ, Hartmann M, et al. Early life antibiotic- driven 
changes in microbiota enhance susceptibility to allergic asthma. 
EMBO Rep. 2012;13:440-447.
 124. Cahenzli J, Koller Y, Wyss M, Geuking MB, McCoy KD. Intestinal mi-
crobial diversity during early- life colonization shapes long- term IgE 
levels. Cell Host Microbe. 2013;14:559-570.
 125. Macpherson AJ, Gatto D, Sainsbury E, Harriman GR, Hengartner 
H, Zinkernagel RM. A primitive T cell- independent mechanism of 
intestinal mucosal IgA responses to commensal bacteria. Science. 
2000;288:2222-2226.
 126. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason 
I. Mucosal antibodies in inflammatory bowel disease are directed 
against intestinal bacteria. Gut. 1996;38:365-375.
 127. Kim D, Kim YG, Seo SU, et al. Nod2- mediated recognition of the mi-
crobiota is critical for mucosal adjuvant activity of cholera toxin. Nat 
Med. 2016;22:524-530.
 128. Zeng MY, Cisalpino D, Varadarajan S, et al. Gut microbiota- induced 
immunoglobulin G controls systemic infection by symbiotic bacteria 
and pathogens. Immunity. 2016;44:647-658.
 129. Zeng MY, Inohara N, Nunez G. Mechanisms of inflammation- driven 
bacterial dysbiosis in the gut. Mucosal Immunol. 2017;10:18-26.
 130. Koch MA, Reiner GL, Lugo KA, et al. Maternal IgG and IgA anti-
bodies dampen mucosal T helper cell responses in early life. Cell. 
2016;165:827-841.
 131. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human in-
testinal microbial flora. Science. 2005;308:1635-1638.
 132. Peterson DA, Frank DN, Pace NR, Gordon JI. Metagenomic ap-
proaches for defining the pathogenesis of inflammatory bowel dis-
eases. Cell Host Microbe. 2008;3:417-427.
 133. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal 
microbiome in inflammatory bowel disease and treatment. Genome 
Biol. 2012;13:R79.
 134. Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems bi-
ology of the human gut microbiome reveals topological shifts associ-
ated with obesity and inflammatory bowel disease. Proc Natl Acad Sci 
USA. 2012;109:594-599.
 135. Lupp C, Robertson ML, Wickham ME, et al. Host- mediated in-
flammation disrupts the intestinal microbiota and promotes the 
overgrowth of Enterobacteriaceae. Cell Host Microbe. 2007;2: 
119-129.
 136. Stecher B, Robbiani R, Walker AW, et al. Salmonella enterica serovar 
typhimurium exploits inflammation to compete with the intestinal 
microbiota. PLoS Biol. 2007;5:2177-2189.
 137. Arthur JC, Perez-Chanona E, Muhlbauer M, et al. Intestinal inflam-
mation targets cancer- inducing activity of the microbiota. Science. 
2012;338:120-123.
 138. Carvalho FA, Koren O, Goodrich JK, et al. Transient inability to man-
age proteobacteria promotes chronic gut inflammation in TLR5- 
deficient mice. Cell Host Microbe. 2012;12:139-152.
 139. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence 
of adherent- invasive Escherichia coli associated with ileal mucosa in 
Crohn’s disease. Gastroenterology. 2004;127:412-421.
 140. Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia 
coli adherence and invasion in Crohn’s disease and colon cancer. 
Gastroenterology. 2004;127:80-93.
 141. Buffie CG, Jarchum I, Equinda M, et al. Profound alterations of in-
testinal microbiota following a single dose of clindamycin results in 
sustained susceptibility to Clostridium difficile- induced colitis. Infect 
Immun. 2012;80:62-73.
 142. Garrett WS, Gallini CA, Yatsunenko T, et al. Enterobacteriaceae act in 
concert with the gut microbiota to induce spontaneous and mater-
nally transmitted colitis. Cell Host Microbe. 2010;8:292-300.
 143. Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the domi-
nant faecal bacterial groups in patients with Crohn’s disease of the 
colon. Gut. 2003;52:237-242.
 144. Gophna U, Sommerfeld K, Gophna S, Doolittle WF, Veldhuyzen van 
Zanten SJ. Differences between tissue- associated intestinal micro-
floras of patients with Crohn’s disease and ulcerative colitis. J Clin 
Microbiol. 2006;44:4136-4141.
 145. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace 
NR. Molecular- phylogenetic characterization of microbial commu-
nity imbalances in human inflammatory bowel diseases. Proc Natl 
Acad Sci USA. 2007;104:13780-13785.
 146. Baumgart M, Dogan B, Rishniw M, et al. Culture independent analy-
sis of ileal mucosa reveals a selective increase in invasive Escherichia 
coli of novel phylogeny relative to depletion of Clostridiales in 
Crohn’s disease involving the ileum. ISME J. 2007;1:403-418.
 147. Wlodarska M, Willing B, Keeney KM, et al. Antibiotic treatment 
alters the colonic mucus layer and predisposes the host to ex-
acerbated Citrobacter rodentium- induced colitis. Infect Immun. 
2011;79:1536-1545.
 148. Spees AM, Wangdi T, Lopez CA, et al. Streptomycin- induced inflam-
mation enhances Escherichia coli gut colonization through nitrate 
respiration. MBio. 2013;4:e00430-13.
 149. Maxwell PR, Rink E, Kumar D, Mendall MA. Antibiotics in-
crease functional abdominal symptoms. Am J Gastroenterol. 
2002;97:104-108.
 150. Mendall MA, Kumar D. Antibiotic use, childhood affluence and 
irritable bowel syndrome (IBS). Eur J Gastro Hepatol. 1998;10: 
59-62.
 151. Matto J, Maunuksela L, Kajander K, et al. Composition and temporal 
stability of gastrointestinal microbiota in irritable bowel syndrome—A 
longitudinal study in IBS and control subjects. FEMS Immunol Med 
Microbiol. 2005;43:213-222.
 152. Krogius-Kurikka L, Lyra A, Malinen E, et al. Microbial community 
analysis reveals high level phylogenetic alterations in the overall 
gastrointestinal microbiota of diarrhoea- predominant irritable bowel 
syndrome sufferers. BMC Gastroenterol. 2009;9:95.
 153. Saulnier DM, Riehle K, Mistretta TA, et al. Gastrointestinal microbi-
ome signatures of pediatric patients with irritable bowel syndrome. 
Gastroenterology. 2011;141:1782-1791.
 154. Kerckhoffs AP, Ben-Amor K, Samsom M, et al. Molecular analysis 
of faecal and duodenal samples reveals significantly higher preva-
lence and numbers of Pseudomonas aeruginosa in irritable bowel syn-
drome. J Med Microbiol. 2011;60:236-245.
88  |     PICKARD et Al.
 155. Pammi M, Cope J, Tarr PI, et al. Intestinal dysbiosis in preterm infants 
preceding necrotizing enterocolitis: A systematic review and meta- 
analysis. Microbiome. 2017;5:31.
 156. Barman M, Unold D, Shifley K, et al. Enteric salmonellosis disrupts 
the microbial ecology of the murine gastrointestinal tract. Infect 
Immun. 2008;76:907-915.
 157. Haag LM, Fischer A, Otto B, et al. Intestinal microbiota shifts to-
wards elevated commensal Escherichia coli loads abrogate coloni-
zation resistance against Campylobacter jejuni in mice. PLoS ONE. 
2012;7:e35988.
 158. Raetz M, Hwang SH, Wilhelm CL, et al. Parasite- induced TH1 cells 
and intestinal dysbiosis cooperate in IFN- gamma- dependent elimi-
nation of Paneth cells. Nat Immunol. 2013;14:136-142.
 159. Ayres JS, Trinidad NJ, Vance RE. Lethal inflammasome activation by 
a multidrug- resistant pathobiont upon antibiotic disruption of the 
microbiota. Nat Med. 2012;18:799-806.
 160. Dicksved J, Ellstrom P, Engstrand L, Rautelin H. Susceptibility to 
Campylobacter infection is associated with the species composition 
of the human fecal microbiota. MBio. 2014;5:e01212-e01214.
 161. Galipeau HJ, McCarville JL, Huebener S, et al. Intestinal microbiota 
modulates gluten- induced immunopathology in humanized mice. Am 
J Pathol. 2015;185:2969-2982.
 162. Cinova J, De Palma G, Stepankova R, et al. Role of intestinal bacteria 
in gliadin- induced changes in intestinal mucosa: Study in germ- free 
rats. PLoS ONE. 2011;6:e16169.
 163. Barnich N, Carvalho FA, Glasser AL, et al. CEACAM6 acts as a recep-
tor for adherent- invasive E. coli, supporting ileal mucosa colonization 
in Crohn disease. J Clin Invest. 2007;117:1566-1574.
 164. Dreux N, Denizot J, Martinez-Medina M, et al. Point mutations in 
FimH adhesin of Crohn’s disease- associated adherent- invasive 
Escherichia coli enhance intestinal inflammatory response. PLoS 
Pathog. 2013;9:e1003141.
 165. Iebba V, Conte MP, Lepanto MS, et al. Microevolution in fimH 
gene of mucosa- associated Escherichia coli strains isolated from 
pediatric patients with inflammatory bowel disease. Infect Immun. 
2012;80:1408-1417.
 166. Koropatkin NM, Cameron EA, Martens EC. How glycan me-
tabolism shapes the human gut microbiota. Nat Rev Microbiol. 
2012;10:323-335.
 167. Fischbach MA, Sonnenburg JL. Eating for two: How metabolism 
establishes interspecies interactions in the gut. Cell Host Microbe. 
2011;10:336-347.
 168. Faith JJ, McNulty NP, Rey FE, Gordon JI. Predicting a human 
gut microbiota’s response to diet in gnotobiotic mice. Science. 
2011;333:101-104.
 169. Sonnenburg ED, Zheng H, Joglekar P, et al. Specificity of polysaccha-
ride use in intestinal bacteroides species determines diet- induced 
microbiota alterations. Cell. 2010;141:1241-1252.
 170. Walker AW, Ince J, Duncan SH, et al. Dominant and diet- responsive 
groups of bacteria within the human colonic microbiota. ISME J. 
2011;5:220-230.
 171. Wu GD, Chen J, Hoffmann C, et al. Linking long- term dietary 
 patterns with gut microbial enterotypes. Science. 2011;334: 
105-108.
 172. Winter SE, Lopez CA, Baumler AJ. The dynamics of gut- associated 
microbial communities during inflammation. EMBO Rep. 
2013;14:319-327.
 173. Garsin DA. Ethanolamine utilization in bacterial pathogens: Roles 
and regulation. Nat Rev Microbiol. 2010;8:290-295.
 174. Velcich A, Yang W, Heyer J, et al. Colorectal cancer in mice 
genetically deficient in the mucin Muc2. Science. 2002;295: 
1726-1729.
 175. Van der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2- deficient 
mice spontaneously develop colitis, indicating that MUC2 is critical 
for colonic protection. Gastroenterology. 2006;131:117-129.
 176. Huang YL, Chassard C, Hausmann M, von Itzstein M, Hennet T. Sialic 
acid catabolism drives intestinal inflammation and microbial dysbio-
sis in mice. Nat Commun. 2015;6:8141.
 177. Bouchet V, Hood DW, Li J, et al. Host- derived sialic acid is incorpo-
rated into Haemophilus influenzae lipopolysaccharide and is a major 
virulence factor in experimental otitis media. Proc Natl Acad Sci USA. 
2003;100:8898-8903.
 178. Cascales E, Buchanan SK, Duche D, et al. Colicin biology. Microbiol 
Mol Biol Rev. 2007;71:158-229.
 179. Nedialkova LP, Denzler R, Koeppel MB, et al. Inflammation fuels colicin 
Ib- dependent competition of Salmonella serovar Typhimurium and E. 
coli in enterobacterial blooms. PLoS Pathog. 2014;10:e1003844.
 180. Ward PP, Uribe-Luna S, Conneely OM. Lactoferrin and host defense. 
Biochem Cell Biol. 2002;80:95-102.
 181. Bachman MA, Miller VL, Weiser JN. Mucosal lipocalin 2 has pro- 
inflammatory and iron- sequestering effects in response to bacterial 
enterobactin. PLoS Pathog. 2009;5:e1000622.
 182. Butala M, Zgur-Bertok D, Busby SJ. The bacterial LexA transcrip-
tional repressor. Cell Mol Life Sci. 2009;66:82-93.
 183. Winter SE, Winter MG, Xavier MN, et al. Host- derived nitrate boosts 
growth of E. coli in the inflamed gut. Science. 2013;339:708-711.
 184. Rivera-Chavez F, Winter SE, Lopez CA, et al. Salmonella uses en-
ergy taxis to benefit from intestinal inflammation. PLoS Pathog. 
2013;9:e1003267.
 185. Winter SE, Thiennimitr P, Winter MG, et al. Gut inflammation 
provides a respiratory electron acceptor for Salmonella. Nature. 
2010;467:426-429.
 186. Lopez CA, Winter SE, Rivera-Chavez F, et al. Phage- mediated acqui-
sition of a type III secreted effector protein boosts growth of salmo-
nella by nitrate respiration. MBio. 2012;3:e00143-12.
 187. Unden G, Bongaerts J. Alternative respiratory pathways of Escherichia 
coli: Energetics and transcriptional regulation in response to electron 
acceptors. Biochem Biophys Acta. 1997;1320:217-234.
 188. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, 
Haase VH. Epithelial hypoxia- inducible factor- 1 is protective in mu-
rine experimental colitis. J Clin Invest. 2004;114:1098-1106.
 189. Lopez CA, Miller BM, Rivera-Chavez F, et al. Virulence factors en-
hance Citrobacter rodentium expansion through aerobic respiration. 
Science. 2016;353:1249-1253.
 190. Skaar EP. The battle for iron between bacterial pathogens and their 
vertebrate hosts. PLoS Pathog. 2010;6:e1000949.
 191. Singh V, Yeoh BS, Xiao X, et al. Interplay between enterobactin, my-
eloperoxidase and lipocalin 2 regulates E. coli survival in the inflamed 
gut. Nat Commun. 2015;6:7113.
 192. Dogan B, Suzuki H, Herlekar D, et al. Inflammation- associated 
adherent- invasive Escherichia coli are enriched in pathways for use 
of propanediol and iron and M- cell translocation. Inflamm Bowel Dis. 
2014;20:1919-1932.
 193. Nash JH, Villegas A, Kropinski AM, et al. Genome sequence of 
adherent- invasive Escherichia coli and comparative genomic analysis 
with other E. coli pathotypes. BMC Genom. 2010;11:667.
 194. Kehl-Fie TE, Chitayat S, Hood MI, et al. Nutrient metal sequestra-
tion by calprotectin inhibits bacterial superoxide defense, enhanc-
ing neutrophil killing of Staphylococcus aureus. Cell Host Microbe. 
2011;10:158-164.
 195. Liu JZ, Jellbauer S, Poe AJ, et al. Zinc sequestration by the neutro-
phil protein calprotectin enhances Salmonella growth in the inflamed 
gut. Cell Host Microbe. 2012;11:227-239.
 196. Diaz-Ochoa VE, Lam D, Lee CS, et al. Salmonella mitigates 
oxidative stress and thrives in the inflamed gut by evading 
calprotectin- mediated manganese sequestration. Cell Host Microbe. 
2016;19:814-825.
 197. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream di-
version on recurrence of Crohn’s disease in the neoterminal ileum. 
Lancet. 1991;338:771-774.
     |  89PICKARD et Al.
 198. D’Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts 
P. Early lesions of recurrent Crohn’s disease caused by infu-
sion of intestinal contents in excluded ileum. Gastroenterology. 
1998;114:262-267.
 199. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metroni-
dazole for the treatment of perianal fistulas in patients with Crohn’s 
disease: A randomized, double- blind, placebo- controlled pilot study. 
Inflamm Bowel Dis. 2009;15:17-24.
 200. Prantera C, Lochs H, Grimaldi M, et al. Rifaximin- extended intestinal 
release induces remission in patients with moderately active Crohn’s 
disease. Gastroenterology. 2012;142(473–481):e474.
 201. Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, Owen MJ. 
T cell receptor- alpha beta- deficient mice fail to develop colitis in the 
absence of a microbial environment. Am J Pathol. 1997;150:91-97.
 202. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin- 10- 
deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
 203. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria 
are necessary for development of spontaneous colitis and immune 
system activation in interleukin- 10- deficient mice. Infect Immun. 
1998;66:5224-5231.
 204. Taurog JD, Richardson JA, Croft JT, et al. The germfree state pre-
vents development of gut and joint inflammatory disease in HLA- 
B27 transgenic rats. J Exp Med. 1994;180:2359-2364.
 205. Garrett WS, Lord GM, Punit S, et al. Communicable ulcerative coli-
tis induced by T- bet deficiency in the innate immune system. Cell. 
2007;131:33-45.
 206. Schaubeck M, Clavel T, Calasan J, et al. Dysbiotic gut microbiota 
causes transmissible Crohn’s disease- like ileitis independent of fail-
ure in antimicrobial defence. Gut. 2016;65:225-237.
 207. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody 
responses to microbial antigens and complications of small bowel 
Crohn’s disease. Gastroenterology. 2004;126:414-424.
 208. Pirzer U, Schonhaar A, Fleischer B, Hermann E, Meyer zum 
Buschenfelde KH. Reactivity of infiltrating T lymphocytes with mi-
crobial antigens in Crohn’s disease. Lancet. 1991;338:1238-1239.
 209. Duchmann R, Neurath MF, Meyer zum Buschenfelde KH. Responses 
to self and non- self intestinal microflora in health and inflammatory 
bowel disease. Res Immunol. 1997;148:589-594.
 210. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant 
antigen in Crohn disease. J Clin Invest. 2004;113:1296-1306.
 211. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 
cell effector cytokines in inflammation. Immunity. 2008;28:454-467.
 212. Klaasen HL, Koopman JP, Van den Brink ME, Bakker MH, Poelma 
FG, Beynen AC. Intestinal, segmented, filamentous bacteria in a wide 
range of vertebrate species. Lab Anim. 1993;27:141-150.
 213. Berry D, Kuzyk O, Rauch I, et al. Intestinal microbiota signatures as-
sociated with inflammation history in mice experiencing recurring 
colitis. Front Microbiol. 2015;6:1408.
 214. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in 
NOD2 associated with susceptibility to Crohn’s disease. Nature. 
2001;411:603-606.
 215. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 
leucine- rich repeat variants with susceptibility to Crohn’s disease. 
Nature. 2001;411:599-603.
 216. Caruso R, Warner N, Inohara N, Nunez G. NOD1 and NOD2: 
Signaling, host defense, and inflammatory disease. Immunity. 
2014;41:898-908.
 217. Rioux JD, Xavier RJ, Taylor KD, et al. Genome- wide association study 
identifies new susceptibility loci for Crohn disease and implicates au-
tophagy in disease pathogenesis. Nat Genet. 2007;39:596-604.
 218. Wellcome Trust Case Control Consortium. Genome- wide associa-
tion study of 14,000 cases of seven common diseases and 3,000 
shared controls. Nature. 2007;447:661-678.
 219. Lapaquette P, Glasser AL, Huett A, Xavier RJ, Darfeuille-Michaud A. 
Crohn’s disease- associated adherent- invasive E. coli are selectively 
favoured by impaired autophagy to replicate intracellularly. Cell 
Microbiol. 2010;12:99-113.
 220. Brest P, Lapaquette P, Souidi M, et al. A synonymous variant in 
IRGM alters a binding site for miR- 196 and causes deregulation 
of IRGM- dependent xenophagy in Crohn’s disease. Nat Genet. 
2011;43:242-245.
 221. Chu H, Khosravi A, Kusumawardhani IP, et al. Gene- microbiota in-
teractions contribute to the pathogenesis of inflammatory bowel 
disease. Science. 2016;352:1116-1120.
 222. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflam-
matory bowel disease. Gastroenterology. 2002;122:44-54.
 223. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity 
of faecal microbiota in Crohn’s disease revealed by a metagenomic 
approach. Gut. 2006;55:205-211.
 224. Scanlan PD, Shanahan F, O’Mahony C, Marchesi JR. Culture- 
independent analyses of temporal variation of the dominant fecal 
microbiota and targeted bacterial subgroups in Crohn’s disease. J 
Clin Microbiol. 2006;44:3980-3988.
 225. Faith JJ, Ahern PP, Ridaura VK, Cheng J, Gordon JI. Identifying gut 
microbe- host phenotype relationships using combinatorial commu-
nities in gnotobiotic mice. Sci Transl Med. 2014;6:220ra211.
 226. Mazmanian SK, Round JL, Kasper DL. A microbial symbio-
sis factor prevents intestinal inflammatory disease. Nature. 
2008;453:620-625.
 227. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is 
an anti- inflammatory commensal bacterium identified by gut mi-
crobiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 
2008;105:16731-16736.
 228. Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally 
selected mixture of Clostridia strains from the human microbiota. 
Nature. 2013;500:232-236.
 229. Gevers D, Kugathasan S, Denson LA, et al. The treatment- naive 
microbiome in new- onset Crohn’s disease. Cell Host Microbe. 
2014;15:382-392.
 230. Shaw KA, Bertha M, Hofmekler T, et al. Dysbiosis, inflammation, and 
response to treatment: A longitudinal study of pediatric subjects 
with newly diagnosed inflammatory bowel disease. Genome Med. 
2016;8:75.
How to cite this article: Pickard JM, Zeng MY, Caruso R, 
Núñez G. Gut microbiota: Role in pathogen colonization, 
immune responses, and inflammatory disease. Immunol Rev. 
2017;279:70–89. https://doi.org/10.1111/imr.12567
